Pyridine-pyrrolo derivative and use thereof in drugs
By developing new pyridinopyrrole derivatives, the problems of insufficient drug properties and poor efficacy of existing TYK2 inhibitors have been solved, efficient inhibition and selectivity of TYK2 have been achieved, and the treatment effect of autoimmune diseases has been significantly improved.
Patent Information
- Application Number
- PCT/CN2024/093809
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
The existing TYK2 inhibitors have problems such as insufficient drug properties, poor efficacy and insufficient kinase selectivity in the treatment of autoimmune diseases, which is difficult to meet the needs of clinical applications.
A new class of pyridinopyrrole derivatives are developed as TYK2 inhibitors, which improves its inhibitory activity and selectivity against TYK2 by optimizing the structure of the compound, and exhibits good pharmacokinetics and safety in animals, avoiding Cardiac toxicity.
It achieves better pharmacological activity, pharmacopolytic properties and lower toxicity, provides better drug properties and higher TYK2 selectivity, significantly improving the therapeutic effect on autoimmune diseases.
Smart Images

Figure CN2024093809_28112024_PF_FP_ABST
Abstract
Description
Pyridopyrrole derivatives and their use in medicine Field of the Invention
[0001] The present invention relates to the field of pharmaceuticals, specifically to a pyridopyrrole derivative and its use in preparing a medicament, particularly a medicament for treating autoimmune diseases. The present invention also relates to a pharmaceutical composition containing the derivative, its use as a TYK2 inhibitor, and its use in preparing a medicament for treating autoimmune diseases.
[0002] Background of the Invention
[0003] Janus kinases (JAKs) are intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals through the JAK-STAT pathway. The JAK family plays a crucial role in cytokine-dependent regulation of proliferation and cellular functions involved in immune responses. Cytokine binding to their receptors triggers receptor dimerization, which promotes reciprocal phosphorylation by JAKs and phosphorylation of specific tyrosine motifs within the cytokine receptors. STATs, which recognize these phosphorylation motifs, are recruited to the receptors and activated through a JAK-dependent tyrosine phosphorylation process. Upon activation, STATs dissociate from their receptors, dimerize, and translocate to the nucleus, where they bind to specific DNA sites and alter transcription.
[0004] Currently, there are four known mammalian JAK family members: JAK1 (Janus kinase-1), JAK2 (Janus kinase-2), JAK3 (Janus kinase, leukocyte, JAKL, L-JAK and Janus kinase-3) and TYK2 (protein tyrosine kinase 2). Different Janus kinase family members are responsible for transmitting signals from different cytokines and their receptors. JAK1, JAK2 and TYK2 are ubiquitously expressed, while JAK3 is reported to be preferentially expressed in natural killer (NK) cells and not in other T cells.
[0005] TYK2 is involved in IFN-α (interferon-α), IL-6 (interleukin-6), IL-10 (interleukin-10), IL-12 (interleukin-12), and IL-23 (interleukin-23) signaling. Biochemical studies and knockout mice have revealed the important role of TYK2 in immunity. TYK2-deficient mice are viable and fertile but exhibit multiple immune defects, primarily hypersusceptibility to infection and defects in tumor surveillance. Conversely, inhibition of TYK2 improves resistance to allergic, autoimmune, and inflammatory diseases. In particular, targeting TYK2 appears to be an innovative strategy for treating diseases mediated by IL-12, IL-23, or type I IFNs. Such diseases include, but are not limited to, rheumatoid arthritis, multiple sclerosis, lupus, psoriasis, psoriatic arthritis, inflammatory bowel disease, uveitis, sarcoidosis, and cancer (Shaw, M. et al., Proc. Natl. Acad. Sci., USA, 2003, 100, 11594-11599; Ortmann, RA, and Shevach, EMC Lin. Immunol, 2001, 98, 109-118; Watford et al, Immunol. Rev., 2004, 202:139).
[0006] Multiple studies have demonstrated the importance of TYK2 in the pathogenesis of autoimmune diseases. For example, rodents with inactivated or chemically inhibited TYK2 have been shown to exhibit resistance to experimental autoimmune disease models such as psoriasis, multiple sclerosis, and inflammatory bowel disease (Michael P et al., "The Interleukin-23 / Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis," Front. Immunol. 2018, 10:3389; Ishizaki M et al., "Involvement of tyrosine kinase-2 in both the IL-12 / Th1 and IL-23 / Th17 axes in vivo." J Immunol. 2011, 187:181-9). Population studies have found that children and adults carrying TYK2 loss-of-activity variants (such as rs12720356 and rs34536443) in the Mestizo population of Mexico have a reduced incidence of SLE (systemic lupus erythematosus) (Cecilia CC et al., “Catalytically Impaired TYK2 Variants are Protective Against Childhood- and Adult-Onset Systemic Lupus Erythematosus in Mexicans” Scientific Reports. 2019, 9:12165). Furthermore, TYK2 SNP mutations have also been reported to be associated with SLE in Nordic, British, and Han Chinese populations. Genome-wide association studies (GWAS) have found that several loss-of-activity variants in TYK2 are significantly associated with resistance to inflammatory diseases, including multiple sclerosis, psoriasis, Crohn's disease, lupus, and rheumatoid arthritis, further suggesting that TYK2 plays an important role in a wide range of autoimmune diseases.(Westra HJ et al., "Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1diabetes" Nat Genet.2018,50:1366-1374; Okada Y et al., "Genetics of rheumatoid arthritis contributes to biology and drug discovery" Nature.2014,506:376-81; Mero IL et al., "A rare variant of the TYK2gene is confirmed to be associated with multiple sclerosis" Eur J Hum Genet.2010,18:502-4; Peluso C et al., "TYK2rs34536443polymorphism is associated with a decreased susceptibility to endometriosis-related infertility" Hum Immunol.2013,74:93-7; Gorman JA et al., "The "TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets" Front Immunol. 2019, 25; 10:44). Therefore, developing drugs that inhibit the effects of TYK2-mediated cytokine signaling pathways has potential therapeutic benefits for human autoimmune diseases.In fact, the highly selective allosteric TYK2 inhibitor BMS986165 has been shown to effectively block the IL-12 / IL-23 and type I IFN signaling pathways, thereby demonstrating significant efficacy in multiple experimental autoimmune disease models (psoriasis, SLE, and IBD) (Tokarski JS et al., "Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain," J Biol Chem. 2015, 290:11061-74). Furthermore, Phase 2 clinical trial results reported that the drug achieved the primary efficacy endpoint in patients with moderate to severe plaque psoriasis and had a favorable risk-benefit ratio. After 12 weeks of taking BMS986165, most patients experienced a decrease in their Psoriasis Area and Severity Index scores of more than 75% (PASI 75), and some patients experienced a decrease in PASI scores of more than 90% (PASI 90) (Kim P. et al., "Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis" N Engl J Med. 2018, 379:1313-1321), further demonstrating the effectiveness and potential of the TYK2 target in the treatment of autoimmune diseases.
[0007] Based on the promising prospects of TYK2-specific inhibitors in the treatment of autoimmune diseases, there is an urgent need to develop a new type of TYK2-selective inhibitor with better drugability, stronger efficacy and higher kinase selectivity.
[0008] Summary of the Invention
[0009] The present invention provides a class of pyridopyrrole derivatives that inhibit, regulate, and / or modulate TYK2 activity, for use in treating inflammatory diseases or autoimmune diseases and their complications. The present invention also provides methods for preparing these compounds, as well as pharmaceutical compositions containing these compounds. The compounds of the present invention and their pharmaceutical compositions have promising clinical application prospects. Compared with existing similar compounds, the compounds of the present invention have better pharmacological activity, pharmacokinetic properties, physicochemical properties, and / or lower toxicity. Specifically, the compounds of the present invention exhibit superior inhibitory activity and high TYK2 selectivity, and demonstrate good absorption and high bioavailability in pharmacokinetic studies in animals. Furthermore, the compounds of the present invention are non-cardiotoxic and have a good safety profile. Therefore, the compounds of the present invention have superior drugability.
[0010] Specifically:
[0011] In one aspect, the present invention relates to a compound as represented by formula (I) or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof of the compound as represented by formula (I).
[0012] in:
[0013] X is N or CR x ;
[0014] Y is N or CR y ;
[0015] Each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy or C 1-6 Alkylamino;
[0016] Ring A is C 3-8 A carbocyclic group or an unsaturated heterocyclic group consisting of 3 to 8 atoms, wherein the C 3-8 The carbocyclic group and the unsaturated heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4, 5 or 6 R 3 substituted by a substituent;
[0017] R 1 NH2, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 substituted by a haloalkyl substituent;
[0018] R 2 H, D, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6Alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 substituted by an alkoxy substituent;
[0019] Each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl composed of 5-12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 substituted with a hydroxyalkyl substituent;
[0020] Or, any two adjacent R 3Together with the atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 substituted by a haloalkoxy substituent;
[0021] R 4 -S(O)R 5 、-S(O)2R 5 、-S(O)2NR 6 R 7 or -NR 6 S(O)2R 7 ;
[0022] Each R 5 H, D, C independently 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 substituted by an alkoxy substituent;
[0023] R 6 and R 7 Each independently is H, D, C 1-6 Alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 substituted by an alkoxy substituent.
[0024] In some embodiments, The substructure is as follows: wherein rings A1, A2, A3 and A4 are each independently optionally substituted with 1, 2, 3, 4, 5 or 6 R 3 substituted by a substituent;
[0025] Each of V1, V2, V3, V4, V5, V6, V7 and V8 is independently -(CH2)-, -O-, -NH-, -(CH2)-O-, -(CH2)-NH-, -C(=O)-, -NH-C(=O)-, -C(=O)-NH-, -OC(=O)-, -C(=O)-O-, -S-, -S(=O)- or -S(=O)2-.
[0026] In some embodiments, The substructure is as follows:
[0027] Each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl composed of 5-12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 substituted with a hydroxyalkyl substituent;
[0028] Or, R 3a 、R 3b Together with the carbon atoms to which they are attached, R 3c 、R 3d Together with the carbon atoms to which they are attached, R 3e 、R 3f Together with the carbon atoms to which they are attached, R 3h 、R 3i Together with the carbon atoms to which they are attached, R 3j 、R 3k Together with the carbon atoms to which they are attached, R 3b 、R 3c Together with the carbon atoms to which they are attached, R 3i 、R 3j Together with the carbon atoms to which they are attached, R 3l 、R 3m Together with the carbon atoms to which they are attached, R 3n 、R 3o Together with the carbon atoms to which they are attached, R 3p 、R 3q Together with the carbon atoms to which they are attached, R 3m 、R 3n Together with the carbon atoms to which they are attached, and, R 3o 、R 3p Together with the carbon atoms to which they are attached, they independently form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6The alkyl group is substituted with a haloalkoxy substituent.
[0029] In some embodiments, each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy or C 1-4 Alkylamino;
[0030] R 1 NH2, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 substituted by a haloalkyl substituent;
[0031] R 2 H, D, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 substituted by an alkoxy substituent.
[0032] In some embodiments, each R x and R yare independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, N-methylamino, N-ethylamino or N,N-dimethylamino;
[0033] R 1 is NH2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl, N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl , N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3 and -CH2CF3;
[0034] R 2 is H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxymethylene, ethoxymethylene, Methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
[0035] In some embodiments, each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 substituted with a hydroxyalkyl substituent;
[0036] Or, any two adjacent R 3 Together with the atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0037] In some embodiments, each R 3are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, -CHF2CH3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl;
[0038] Or, any two adjacent R 3 Together with the atoms to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0039] In some embodiments, each R 5 H, D, C independently 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C 1-4 substituted by an alkoxy substituent;
[0040] R 6 and R 7 Each independently is H, D, C 1-4 Alkyl, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C1-4 substituted by an alkoxy substituent.
[0041] In some embodiments, each R 5 are independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy;
[0042] R 6 and R 7 Each is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl , cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
[0043] In some embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 substituted with a hydroxyalkyl substituent;
[0044] Or, R 3a 、R 3b Together with the carbon atoms to which they are attached, R 3c 、R 3d Together with the carbon atoms to which they are attached, R 3e 、R 3f Together with the carbon atoms to which they are attached, R 3h 、R 3i Together with the carbon atoms to which they are attached, R 3j 、R 3k Together with the carbon atoms to which they are attached, R 3b 、R 3c Together with the carbon atoms to which they are attached, R 3i 、R 3jTogether with the carbon atoms to which they are attached, R 3l 、R 3m Together with the carbon atoms to which they are attached, R 3n 、R 3o Together with the carbon atoms to which they are attached, R 3p 、R 3q Together with the carbon atoms to which they are attached, R 3m 、R 3n Together with the carbon atoms to which they are attached, and, R 3o 、R 3p Together with the carbon atoms to which they are attached, they independently form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0045] In some embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl;
[0046] Or, R 3a 、R 3b Together with the carbon atoms to which they are attached, R 3c 、R3d Together with the carbon atoms to which they are attached, R 3e 、R 3f Together with the carbon atoms to which they are attached, R 3h 、R 3i Together with the carbon atoms to which they are attached, R 3j 、R 3k Together with the carbon atoms to which they are attached, R 3b 、R 3c Together with the carbon atoms to which they are attached, R 3i 、R 3j Together with the carbon atoms to which they are attached, R 3l 、R 3m Together with the carbon atoms to which they are attached, R 3n 、R 3o Together with the carbon atoms to which they are attached, R 3p 、R 3q Together with the carbon atoms to which they are attached, R 3m 、R 3n Together with the carbon atoms to which they are attached, and, R 3o 、R 3p and the carbon atoms to which they are attached, each independently forms a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0047] In one aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) of the present invention, or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.
[0048] In some embodiments, the pharmaceutical composition of the present invention further comprises at least one of pharmaceutically acceptable excipients, vehicles, carriers, and solvents.
[0049] In another aspect, the present invention relates to use of the compound or pharmaceutical composition disclosed in the present invention in the preparation of a medicament for preventing, managing, treating or alleviating a TYK2-mediated disease.
[0050] In some embodiments, the TYK2-mediated disease of the present invention is a viral disease, a genetic disease, an inflammatory disease, or an autoimmune disease.
[0051] In other embodiments, the TYK2-mediated disease of the present invention is multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome or scleroderma.
[0052] In another aspect, the present invention relates to use of the compound or pharmaceutical composition disclosed in the present invention in preparing a medicament for inhibiting the activity of JAK.
[0053] In some embodiments, the compounds or pharmaceutical compositions disclosed herein are prepared for use in inhibiting the activity of TYK2.
[0054] In yet another aspect, the present invention relates to methods for preparing, isolating and purifying the compounds encompassed by formula (I).
[0055] The results of biological tests show that the compounds provided by the present invention can be used as good JAK inhibitors, especially as TYK2 inhibitors.
[0056] Any embodiments of any aspect of the present invention may be combined with other embodiments, as long as they do not conflict. In addition, in any embodiments of any aspect of the present invention, any technical feature may be applicable to the technical features in other embodiments, as long as they do not conflict.
[0057] The foregoing description only summarizes certain aspects of the present invention, but is not intended to limit the present invention to these aspects. These and other aspects will be described in more detail and fully below.
[0058] Detailed description of the present invention
[0059] Definitions and General Terms
[0060] Certain embodiments of the present invention will now be described in detail, examples of which are illustrated by the accompanying structural formulae and chemical formulae. The present invention is intended to encompass all alternatives, modifications, and equivalent technical solutions, which are all included within the scope of the invention as defined in the claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated literature, patents, and similar materials differ from or contradict the present invention (including but not limited to defined terms, term applications, described techniques, etc.), the present invention shall prevail.
[0061] It will be further appreciated that certain features of the invention, which, for clarity, are described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which, for brevity, are described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
[0062] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.
[0063] Unless otherwise indicated, the following definitions used in the present invention shall apply. For purposes of the present invention, chemical elements are consistent with the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th edition, 1994. In addition, general principles of organic chemistry can be found in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.
[0064] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example" or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0065] Unless otherwise specified or clearly contradicted by context, the articles "a," "an," and "the" as used herein are intended to include "at least one" or "one or more." Thus, as used herein, these articles refer to one or more than one (i.e., at least one) of the objects. For example, "a component" refers to one or more components, i.e., more than one component may be contemplated for use or use in implementing the described embodiment.
[0066] As used herein, the term "subject" refers to an animal. Typically, the animal is a mammal. A subject also refers, for example, to primates (e.g., humans, male or female), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.
[0067] The term "patient" used in the present invention refers to humans (including adults and children) or other animals. In some embodiments, "patient" refers to humans.
[0068] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.
[0069] "Stereoisomers" are compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans isomers), atropisomers, and the like.
[0070] "Chiral" refers to a molecule that is non-superimposable on its mirror image; "achiral" refers to a molecule that is superimposable on its mirror image.
[0071] "Enantiomers" refer to two non-superimposable isomers of a compound that are mirror images of each other.
[0072] "Diastereoisomers" refer to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of one another. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivities. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as electrophoresis and chromatography, for example, HPLC.
[0073] Stereochemical definitions and conventions used herein generally follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994.
[0074] Many organic compounds exist in optically active forms, meaning they have the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are the symbols used to designate the rotation of plane-polarized light caused by the compound, where (-) or l indicates that the compound is left-handed. A compound prefixed with (+) or d is right-handed. A specific stereoisomer is an enantiomer, and a mixture of such isomers is called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process.
[0075] Any asymmetric atom (e.g., carbon, etc.) of the compounds disclosed herein can exist in a racemic or enantiomerically enriched form, such as in the (R)-, (S)-, or (R,S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in terms of the (R)- or (S)-configuration.
[0076] Depending on the choice of starting materials and process, the compounds of the present invention may exist as one of the possible isomers or as a mixture thereof, such as a racemate or a mixture of diastereoisomers (depending on the number of asymmetric carbon atoms). Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may be in the cis or trans configuration.
[0077] Any resulting mixture of stereoisomers can be separated into the pure or substantially pure geometric isomers, enantiomers, and diastereomers on the basis of the differences in the constituent physicochemical properties, for example, by chromatography and / or fractional crystallization.
[0078] Any racemate of the resulting final product or intermediate can be separated into its optical antipodes by methods familiar to those skilled in the art using known methods, such as by separating the salts of the diastereoisomers obtained. The racemic products can also be separated by chiral chromatography, such as high performance liquid chromatography (HPLC) using a chiral adsorbent. In particular, enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2 nd Ed.Robert E.Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012); Eliel, ELStereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SHTables of Resolving Agents and Optical Resolutions p.268 (ELEliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972); Chiral Separation Techniques: A Practical Approach (Subramanian, G.Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007).
[0079] The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that can be converted into each other through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of the tautomers can be reached. For example, proton tautomers (also known as prototropic tautomers) include interconversions performed by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions performed by the reorganization of some bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridine-4-ol and pyridine-4(1H)-one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
[0080] As described herein, the compounds of the present invention may be optionally substituted with one or more substituents, such as the compounds of the general formula above, or as described in the specific examples, subclasses, and classes of compounds encompassed by the present invention.
[0081] In general, the term "substituted" means that one or more substitutable hydrogen atoms in a given structure are replaced with a specified substituent. Unless otherwise indicated, a substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure is substitutable with one or more substituents selected from a specified group, the substituents may be the same or different at each position.
[0082] The term "optional" or "optionally" means that the subsequently described event or circumstance can but need not occur, including instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that the alkyl group can but need not be present, including instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0083] The term "unsubstituted" means that the designated group bears no substituents.
[0084] The term "optionally substituted with" can be used interchangeably with the term "unsubstituted or substituted with," meaning that the structure is unsubstituted or substituted with one or more substituents described herein.
[0085] In addition, it should be noted that, unless otherwise explicitly stated, the description methods used in the present invention, "each...independently is" and "...each independently is" and "...independently is" can be interchanged and should be understood in a broad sense. It can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or it can mean that in the same group, the specific options expressed by the same symbols do not affect each other.
[0086] In various parts of this specification, substituents of compounds disclosed herein are disclosed in terms of group types or ranges. It is specifically noted that the present invention includes every independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl as disclosed independently.
[0087] In various parts of the present invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood to be a linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.
[0088] The term "alkyl" or "alkyl group" as used herein refers to a saturated, straight-chain or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, an alkyl group contains 1-20 carbon atoms. In some embodiments, the alkyl group contains 1-12 carbon atoms; in other embodiments, the alkyl group contains 2-12 carbon atoms; in other embodiments, the alkyl group contains 1-6 carbon atoms; in other embodiments, the alkyl group contains 2-6 carbon atoms; in yet other embodiments, the alkyl group contains 1-4 carbon atoms; and in still other embodiments, the alkyl group contains 1-3 carbon atoms.
[0089] Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -C(CH3) )3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 2,2-dimethylpropyl (neopentyl, -CH2C(CH3)2CH3), 3-methyl-1-butyl (-CH2CH2C H(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH 3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, and the like.
[0090] The term "alkoxy" refers to an alkyl group attached to the remainder of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; and in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein.
[0091] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.
[0092] The terms "hydroxyalkyl" and "hydroxyalkoxy" refer to an alkyl or alkoxy group substituted with one or more hydroxy substituents, wherein "hydroxyalkyl" and "hydroxyalkyl" are used interchangeably, such examples include, but are not limited to, hydroxymethyl (-CH2OH), hydroxyethyl (-CH2CH2OH, -CH(OH)CH3), hydroxypropyl (-CH2CH2CH2OH, -CH2CH(OH)CH 3, -CH(OH)CH2CH3), hydroxymethoxy (-OCH2OH), etc.
[0093] The term "haloalkoxy" refers to an alkoxy group substituted by one or more halogen atoms, wherein alkoxy has the meaning described herein; such examples include, but are not limited to, difluoromethoxy (-OCHF2), trifluoromethoxy (-OCF3), and the like.
[0094] The term "haloalkyl" refers to an alkyl group substituted with one or more halogen atoms, wherein alkyl has the meaning herein. In some embodiments, the haloalkyl group contains 1-12 carbon atoms; in other embodiments, the haloalkyl group contains 1-10 carbon atoms; in other embodiments, the haloalkyl group contains 1-8 carbon atoms; in other embodiments, the haloalkyl group contains 1-6 carbon atoms; in other embodiments, the haloalkyl group contains 1-4 carbon atoms; and in other embodiments, the haloalkyl group contains 1-3 carbon atoms. Examples include, but are not limited to, difluoromethyl (-CHF2), trifluoromethyl (-CF3), 2,2-difluoroethyl (-CH2CHF2), 2,2,2-trifluoroethyl (-CH2CF3), and the like.
[0095] The terms "alkylamino" and "alkylamino" are used interchangeably and include "N-alkylamino" and "N,N-dialkylamino" wherein the amino groups are independently substituted with one or two alkyl substituents. In some embodiments, the alkylamino group is one or two C 1-12 In other embodiments, the alkylamino group is one or two C 1-6 In other embodiments, the alkylamino group is one or two C 1-4 In some other embodiments, the alkylamino group is one or two C 1-3 Alkyl is connected to the nitrogen atom to form a lower alkylamino group. Suitable alkylamino groups can be monoalkylamino or dialkylamino. Examples of alkylamino groups include, but are not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.
[0096] The term "alkoxyalkyl" refers to an alkyl group substituted by one or more alkoxy groups, wherein alkoxy and alkyl are as defined above. Examples of alkoxyalkyl groups include, but are not limited to, methylmethylene (-CH2OCH3) and ethoxymethylene (-CH2OCH2CH3).
[0097] The term "carbocyclyl" or "carbocycle" refers to a monovalent or polyvalent, non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms. Carbobicyclic groups include spirocarbobicyclic groups, fused carbobicyclic groups and bridged carbobicyclic groups. Suitable carbocyclyl groups include, but are not limited to, cycloalkyl, cycloalkenyl and cycloalkynyl groups. Examples of carbocyclyl groups further include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-alkenyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, etc.
[0098] The term "cycloalkyl" refers to a monovalent or multivalent saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms. In some embodiments, the cycloalkyl group contains 3 to 12 carbon atoms; in other embodiments, the cycloalkyl group contains 3 to 8 carbon atoms; in other embodiments, the cycloalkyl group contains 4 to 7 carbon atoms; in other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms. In some embodiments, the cycloalkyl group contains 7 to 12 carbon atoms, i.e., C 7-12 Cycloalkyl further comprising C 7-12 Spirobicycloalkyl, C 7-12 Fused bicycloalkyl and C 7-12 In other embodiments, the cycloalkyl group is a group containing 8 to 11 carbon atoms, i.e., C 8-11 Cycloalkyl further comprising C 8-11 Spirobicycloalkyl, C 8-11 Fused bicycloalkyl and C 8-11 In some embodiments, C 3-6 Cycloalkyl specifically refers to a ring containing 3-6 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl groups can be independently unsubstituted or substituted with one or more substituents described herein.
[0099] The terms "heterocyclyl" and "heterocycle" are used interchangeably herein and refer to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic, bicyclic or tricyclic ring system containing 3 to 12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the heterocyclyl group can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxygen compound. Heterocyclyl groups include saturated heterocyclyl groups (i.e., heterocycloalkyl groups) and partially unsaturated heterocyclyl groups. In some embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3 to 8 atoms; in other embodiments, the heterocyclyl group is a heterocyclyl group consisting of 3 to 6 atoms.
[0100] Examples of heterocyclic groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepine Base (eg, 1,4-oxazepine 1,2-oxazepine yl), diazepine Base (eg, 1,4-diazepine 1,2-diazepine yl), dioxa Base (eg, 1,4-dioxa 1,2-dioxa yl), thiazolin Base (such as 1,4-thiazepine 1,2-thiazepine 1-H-isoindolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,3-benzodioxolyl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, 2-azaspiro[4.4]nonanyl, 2-oxaspiro[3.3]heptanyl, 1,6-dioxaspiro[4.4]nonanyl, 2-azaspiro[4.5]decanyl, 8-azaspiro[4.5]decanyl, 7-azaspiro[4.5]decanyl, 3-azaspiro[5.5]undecyl, 2-azaspiro[5.5]undecyl, octahydro-1H-isoindolyl, octahydrocyclopenta[c]pyrrolyl, hexahydrofuro[3,2-b]furanyl, and dodecahydroisoquinolinyl, among others. Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 1,1-dioxoisothiazolidinone-2-yl, pyrrolidin-2-one-1-yl, imidazolidin-2-one-1-yl, oxazolidin-2-one-3-yl, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidonyl, and 3,5-dioxopiperidinyl. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, sulfolane, 1,1-dioxothiomorpholinyl, 1,1-dioxotetrahydrothiophenyl, and 1,1-dioxotetrahydro-2H-thiopyranyl. The heterocyclic group may be optionally substituted with one or more substituents described herein.
[0101] As used herein, the term "unsaturated" means that the group contains one or more degrees of unsaturation.
[0102] The term "heteroatom" refers to O, S, N, P and Si, including any oxidation state of N, S and P; primary, secondary, tertiary amines and quaternary ammonium salts; or the hydrogen on the nitrogen atom in the heterocyclic ring is substituted, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl, R is a substituent described herein).
[0103] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
[0104] The term "aryl" refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system comprises a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups include phenyl, naphthyl, and anthracenyl. The aryl groups can be independently and optionally substituted with one or more substituents described herein.
[0105] The term "heteroaryl" refers to aromatic monocyclic, bicyclic, and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, with at least one ring system containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each ring system contains 5-7 ring atoms and has one or more points of attachment to the rest of the molecule. The term "heteroaryl" can be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound."
[0106] Examples of heteroaryl groups include, but are in no way limited to, benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (e.g., 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), purinyl, quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, or 4-isoquinolyl), indazolyl (e.g., 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, Pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, imidazo[1,2-c]pyrimidinyl, 1H-benzo[d][1,2,3]triazolyl, 3H-imidazo[4,5-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-benzo[d]imidazolyl, 1H-pyrazolo[3,2-b]pyridinyl, [1,2,4]triazolo[1,5-a] ] pyridyl, purinyl, furanyl (such as 2-furyl, 3-furyl), imidazolyl (such as 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (such as 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxazolyl (such as 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrrolyl (such as 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (such as 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridonyl, pyrimidinyl (such as 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrimidonyl, pyrimidinedione, pyridazinyl (such as 3-pyridazinyl, 4-pyridazinyl), pyrazinyl (such as 2-pyridyl, 3-pyridyl, 4-pyridyl), 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl), 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl and 1,3,5-triazinyl.
[0107] The term "-C 1-6 Alkylene (cycloalkyl)", "-C 1-6"Alkylene (heterocyclyl)" means that cycloalkyl and heterocyclyl are connected to the rest of the molecule through alkylene, wherein alkylene, cycloalkyl and heterocyclyl have the meanings as described in the present invention. 1-6 Alkylene (cycloalkyl)", "-C 1-6 Alkylene (heterocyclyl)" is optionally substituted with one or more substituents described herein. In some embodiments, the "-C 1-6 Alkylene (cycloalkyl)" can be "-C 1-6 Alkylene (-C 3-6 In some embodiments, the "-C 1-6 Alkylene (heterocyclic)" can be "-C 1-6 Alkylene (heterocyclic group consisting of 3-6 atoms)".
[0108] The term "alkylene" refers to a saturated divalent or polyvalent hydrocarbon radical derived by removing two or more hydrogen atoms from a saturated straight-chain or branched hydrocarbon radical. Unless otherwise specified, an alkylene group contains 1-12 carbon atoms. In some embodiments, an alkylene group contains 1-6 carbon atoms; in other embodiments, an alkylene group contains 1-4 carbon atoms; in still other embodiments, an alkylene group contains 1-3 carbon atoms; and in still other embodiments, an alkylene group contains 1-2 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), n-propylene (-CH2CH2CH2-), isopropylene (-CH(CH3)CH2-), and the like.
[0109] The term "any two adjacent R's together with the atoms to which they are attached form a cycloalkyl or heterocyclyl" means "two R's on two adjacent carbon atoms together with the atoms to which they are attached form a cycloalkyl or heterocyclyl" and "R's attached to the same carbon atom together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl.
[0110] The term "prodrug" as used in the present invention refers to a compound that is converted into a compound represented by formula (I) in vivo. Such conversion is affected by the hydrolysis of the prodrug in the blood or by enzyme conversion to the parent structure in the blood or tissue. The prodrug compound of the present invention can be an ester. In the existing invention, esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, a compound of the present invention containing a hydroxyl group can be acylated to produce a prodrug form of the compound. Other prodrug forms include phosphate esters, such as these phosphate ester compounds, which are obtained by phosphorylating a hydroxyl group on the parent compound. For a complete discussion of prodrugs, see T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and SJ Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345.
[0111] "Metabolite" refers to a product resulting from the in vivo metabolism of a specific compound or salt thereof. Metabolites of a compound can be identified using techniques known in the art, and their activity can be characterized using assays such as those described herein. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention encompasses metabolites of the compound, including metabolites produced by contacting a compound of the invention with a mammal for a sufficient period of time.
[0112] As used herein, "pharmaceutically acceptable salts" refer to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in S.M. Berge et al., "Describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19." Pharmaceutically acceptable salts formed from non-toxic acids include, but are not limited to, inorganic acid salts formed by reaction with amino groups, such as hydrochlorides, hydrobromides, phosphates, sulfates, and perchlorates, and organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, and malonates, or salts obtained by other methods described in the literature, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C1-C4 alkyl) 4 salts. The present invention also contemplates quaternary ammonium salts formed by any compound containing a N group. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C 1-8 Sulfonates and aromatic sulfonates.
[0113] As used herein, a "solvate" refers to an association formed between one or more solvent molecules and a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association formed when the solvent molecule is water.
[0114] As used herein, the term "treating" any disease or condition, in some embodiments, refers to ameliorating the disease or condition (i.e., slowing or arresting or alleviating the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" refers to regulating the disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, "treating" refers to preventing or delaying the onset, occurrence, or worsening of a disease or condition.
[0115] As used herein, "inflammatory disease" refers to any disease, disorder, or condition characterized by excessive inflammatory symptoms, host tissue damage, or loss of tissue function resulting from an excessive or uncontrolled inflammatory response. "Inflammatory disease" also refers to a pathological state mediated by leukocyte influx and / or neutrophil chemotaxis.
[0116] As used herein, "inflammation" refers to a local protective response caused by tissue damage or destruction, which serves to destroy, dilute, or isolate (isolate) harmful substances and damaged tissue. Inflammation is significantly associated with leukocyte influx and / or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses, as well as non-infectious causes such as trauma or reperfusion following myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune responses. Therefore, inflammatory diseases that can be treated with the compounds disclosed herein include diseases associated with specific defense system responses as well as non-specific defense system responses.
[0117] "Specific defense system" refers to the components of the immune system that respond to the presence of specific antigens. Examples of inflammation resulting from specific defense system reactions include classical responses to foreign antigens, autoimmune diseases, and delayed hypersensitivity responses (mediated by T-cells). Chronic inflammatory diseases, rejection of transplanted solid tissues and organs (such as rejection of kidney and bone marrow transplants), and graft-versus-host disease (GVHD) are other examples of specific defense system inflammatory responses.
[0118] As used herein, "autoimmune disease" refers to a collection of any diseases that involve tissue damage associated with a humoral or cell-mediated response to the body's own components.
[0119] As used herein, "allergy" refers to any symptom, tissue damage or loss of tissue function that produces an allergy. As used herein, "arthritis disease" refers to any disease characterized by arthritis damage attributable to various etiologies. As used herein, "dermatitis" refers to any one of a large family of skin diseases characterized by skin inflammation attributable to various etiologies. As used herein, "transplant rejection" refers to any immune response against transplanted tissues, such as organs or cells (such as bone marrow), characterized by loss of function, pain, swelling, leukocytosis and thrombocytopenia of the transplanted or surrounding tissues. The therapeutic methods of the present invention include methods for treating diseases associated with inflammatory cell activation.
[0120] Description of the compounds of the present invention
[0121] The present invention discloses a novel class of compounds which can be used as JAK inhibitors and can be used to treat diseases associated with JAK activity, in particular diseases associated with TYK2 activity, such diseases including viral diseases, genetic diseases, inflammatory diseases or autoimmune diseases.
[0122] In one aspect, the present invention relates to a compound as represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof of the compound as represented by formula (I).
[0123] Among them, each R 1 、R 2 、R 4 , X, Y and ring A all have the meanings described in the present invention.
[0124] In some embodiments, Ring A is C 3-8 A carbocyclic group or an unsaturated heterocyclic group consisting of 3 to 8 atoms, wherein the C 3-8 The carbocyclic group and the unsaturated heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4, 5 or 6 R 3 Substituted by a substituent; wherein R 3 has the meanings described in the present invention.
[0125] In some embodiments, X is N or CR x ; where R x has the meanings described in the present invention.
[0126] In some embodiments, Y is N or CR y ; where R y has the meanings described in the present invention.
[0127] In some embodiments, each R x and Ry are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy or C 1-6 Alkylamino.
[0128] In some embodiments, each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy or C 1-4 Alkylamino.
[0129] In other embodiments, each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, N-methylamino, N-ethylamino or N,N-dimethylamino.
[0130] In some embodiments, Ring A is C 3-8 A carbocyclic group or an unsaturated heterocyclic group consisting of 3 to 8 atoms, wherein the C 3-8 The carbocyclic group and the unsaturated heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4, 5 or 6 R 3 substituted by a substituent.
[0131] In some embodiments, R 1 NH2, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 The alkyl group is substituted by a haloalkyl substituent.
[0132] In some embodiments, R1 NH2, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 The alkyl group is substituted by a haloalkyl substituent.
[0133] In other embodiments, R 1 is NH2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl, N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl , N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3 and -CH2CF3.
[0134] In some embodiments, R 2 H, D, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 substituted by an alkoxy substituent.
[0135] In some embodiments, R 2 H, D, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 substituted by an alkoxy substituent.
[0136] In other embodiments, R 2 is H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxymethylene, ethoxymethylene, Methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
[0137] In some embodiments, each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl composed of 5-12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a hydroxyalkyl substituent.
[0138] In some embodiments, each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10The aryl group and the heteroaryl group consisting of 5-10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a hydroxyalkyl substituent.
[0139] In some embodiments, each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl.
[0140] In some embodiments, each R 3are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropyl, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -methylene(cyclopropyl), -methylene(cyclobutyl), yl), -methylene(cyclopentyl), -methylene(cyclohexyl), -methylene(oxetanyl), -methylene(azetidinyl), -methylene(pyrrolidinyl), -methylene(tetrahydrofuranyl), -methylene(tetrahydropyranyl), -methylene(tetrahydrothiopyranyl), -methylene(piperidinyl), -methylene(piperazinyl), -methylene(morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl , n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -methylene(cyclopropyl), -methylene(cyclobutyl), -methylene(cyclopentyl), -methylene(cyclohexyl), -methylene(oxetanyl), -methylene(azetidinyl), -methylene(pyrrolidinyl), -methylene(tetrahydrofuranyl), -methylene(tetrahydropyranyl), -methylene( , -methylene(piperidinyl), -methylene(piperazinyl), -methylene(morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl.
[0141] In some embodiments, any two adjacent R 3 Together with the atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0142] In some embodiments, any two adjacent R 3 Together with the atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0143] In other embodiments, any two adjacent R 3 Together with the atoms to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0144] In some embodiments, any two R attached to the same carbon atom 3 Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0145] In some embodiments, any two R attached to the same carbon atom 3 Together with the carbon atoms to which they are attached, they form C 3-6Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0146] In other embodiments, any two R attached to the same carbon atom 3 and the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0147] In some embodiments, R 4 -S(O)R 5 、-S(O)2R 5 、-S(O)2NR 6 R 7 or -NR 6 S(O)2R 7 ; where R 5 、R 6 and R 7 has the meanings described in the present invention.
[0148] In some embodiments, each R 5 H, D, C independently 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 substituted by an alkoxy substituent.
[0149] In some embodiments, each R 5 H, D, C independently 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C 1-4 substituted by an alkoxy substituent.
[0150] In other embodiments, each R 5 are independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
[0151] In some embodiments, R 6 and R 7 Each independently is H, D, C 1-6 Alkyl, C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 substituted by an alkoxy substituent.
[0152] In some embodiments, R 6 and R 7 Each independently is H, D, C 1-4 Alkyl, C3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C 1-4 substituted by an alkoxy substituent.
[0153] In other embodiments, R 6 and R 7 Each is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl , cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
[0154] In some embodiments, The substructure is as follows: wherein rings A1, A2, A3 and A4 are each independently optionally substituted with 1, 2, 3, 4, 5 or 6 R 3 Substituted by a substituent; wherein X, Y, R 3 、R 4 , V1, V2, V3, V4, V5, V6, V7 and V8 have the meanings described in the present invention.
[0155] In some embodiments, The substructure is as follows: Where X, Y, R 4 、 R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3 has the meanings described in the present invention.
[0156] In some embodiments, each of V1, V2, V3, V4, V5, V6, V7 and V8 is independently -(CH2)-, -O-, -NH-, -(CH2)-O-, -(CH2)-NH-, -C(=O)-, -NH-C(=O)-, -C(=O)-NH-, -OC(=O)-, -C(=O)-O-, -S-, -S(=O)- or -S(=O)2-.
[0157] In some embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl composed of 5-12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C3-8 Cycloalkyl, heterocyclic group composed of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a hydroxyalkyl substituent.
[0158] In some embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group composed of 3-6 atoms, -C1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5-10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a hydroxyalkyl substituent.
[0159] In some embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuryl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl.
[0160] In other embodiments, each R 3a 、R 3b 、R 3c 、R 3d 、R 3e 、R 3f 、R 3g 、R 3h 、R 3i 、R 3j 、R 3k 、R 3l 、R 3m 、R 3n 、R 3o 、R 3p and R 3qare independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -methylene(cyclopropyl), -methylene(cyclopentyl ... butyl), -methylene(cyclopentyl), -methylene(cyclohexyl), -methylene(oxetanyl), -methylene(azetidinyl), -methylene(pyrrolidinyl), -methylene(tetrahydrofuranyl), -methylene(tetrahydropyranyl), -methylene(tetrahydrothiopyranyl), -methylene(piperidinyl), -methylene(piperazinyl), -methylene(morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl alkyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -methylene(cyclopropyl), -methylene(cyclobutyl), -methylene(cyclopentyl), -methylene(cyclohexyl), -methylene(oxetanyl), -methylene(azetidinyl), -methylene(pyrrolidinyl), -methylene(tetrahydrofuranyl), -methylene(tetrahydropyranyl), -methylene (tetrahydrothiopyranyl), -methylene(piperidinyl), -methylene(piperazinyl), -methylene(morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl.
[0161] In some embodiments, R 3a 、R 3b Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0162] In some embodiments, R 3a 、R 3b Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0163] In other embodiments, R 3a 、R 3b Together with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0164] In some embodiments, R 3c 、R 3d Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0165] In some embodiments, R 3c 、R 3d Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0166] In other embodiments, R 3c 、R 3d and the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0167] In some embodiments, R 3e 、R 3f Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0168] In some embodiments, R 3e 、R 3f Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0169] In other embodiments, R 3e 、R 3f Together with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0170] In some embodiments, R 3h 、R 3i Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0171] In some embodiments, R 3h 、R 3i Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0172] In other embodiments, R 3h 、R 3iTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0173] In some embodiments, R 3j 、R 3k Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0174] In some embodiments, R 3j 、R 3k Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0175] In other embodiments, R 3j 、R 3kTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0176] In some embodiments, R 3b 、R 3c Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0177] In some embodiments, R 3b 、R 3c Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0178] In other embodiments, R 3b 、R 3cTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0179] In some embodiments, R 3i 、R 3j Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0180] In some embodiments, R 3i 、R 3j Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0181] In other embodiments, R 3i 、R 3jTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0182] In some embodiments, R 3l 、R 3m Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0183] In some embodiments, R 3l 、R 3m Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0184] In other embodiments, R 3l 、R 3mTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0185] In some embodiments, R 3n 、R 3o Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0186] In some embodiments, R 3n 、R 3o Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0187] In other embodiments, R 3n 、R 3oTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0188] In some embodiments, R 3p 、R 3q Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0189] In some embodiments, R 3p 、R 3q Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0190] In other embodiments, R 3p 、R 3qTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0191] In some embodiments, R 3m 、R 3n Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0192] In some embodiments, R 3m 、R 3n Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0193] In other embodiments, R 3m 、R 3nTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0194] In some embodiments, R 3o 、R 3p Together with the carbon atoms to which they are attached, they form C 3-8 Cycloalkyl or heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy and C 1-6 The alkyl group is substituted with a haloalkoxy substituent.
[0195] In some embodiments, R 3o 、R 3p Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or heterocyclic group consisting of 3-6 atoms, wherein the C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Alkoxy and C 1-4 The alkyl group is substituted with a haloalkoxy substituent.
[0196] In other embodiments, R 3o 、R 3pTogether with the carbon atom to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein said cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from the group consisting of D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
[0197] In another aspect, the present invention relates to one of the following compounds or a stereoisomer, tautomer, N-oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof, but is in no way limited to:
[0198] Unless otherwise indicated, stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof of the compound represented by formula (I) are all within the scope of the present invention.
[0199] The compounds disclosed herein may contain asymmetric or chiral centers and, therefore, may exist in different stereoisomeric forms. The present invention is intended to include all stereoisomeric forms of the compounds of formula (I), including but not limited to diastereomers, enantiomers, atropisomers, and geometric (or conformational) isomers, as well as mixtures thereof, such as racemic mixtures, as part of the present invention.
[0200] In structures disclosed herein, when the stereochemistry of any particular chiral atom is not indicated, all stereoisomers of the structure are contemplated and included as compounds disclosed herein. When stereochemistry is indicated by a solid wedge or dashed line representing a specific configuration, the stereoisomers of the structure are unambiguous and defined.
[0201] The compound represented by formula (I) may exist in different tautomeric forms, and all of these tautomers, such as the tautomers described in the present invention, are included within the scope of the present invention.
[0202] The compound shown in formula (I) may exist in the form of a salt. In some embodiments, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. In other embodiments, the salt is not necessarily a pharmaceutically acceptable salt and can be an intermediate for preparing and / or purifying the compound shown in formula (I) and / or for separating the enantiomers of the compound shown in this formula (I).
[0203] Pharmaceutically acceptable acid addition salts can be formed by reacting the compound represented by formula (I) with an inorganic acid or an organic acid, such as acetate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlorophylline, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalactonate, propionate, stearate, succinate, sulfosalicylate, tartrate, toluenesulfonate and trifluoroacetate.
[0204] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
[0205] Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, sulfosalicylic acid, and the like.
[0206] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
[0207] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from Groups I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.
[0208] Organic bases from which salts can be derived include primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include, for example, isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.
[0209] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, the basic or acidic moiety using conventional chemical methods. Generally speaking, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of a suitable base (such as a hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg or K), or by reacting the free base form of these compounds with a stoichiometric amount of a suitable acid. Such reactions are generally carried out in water or an organic solvent or a mixture of the two. Generally, where appropriate, a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile is used. Additional lists of suitable salts can be found, for example, in "Remington's Pharmaceutical Sciences", 20th edition, Mack Publishing Company, Easton, Pa., (1985); and "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
[0210] In addition, the compounds disclosed herein, including their salts, can also be obtained in the form of their hydrates or in the form of solvents (e.g., ethanol, DMSO, etc.) for their crystallization. The compounds disclosed herein can inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, the present invention is intended to include both solvated and unsolvated forms.
[0211] Any structural formula given herein is also intended to represent non-isotopically enriched as well as isotopically enriched forms of these compounds. Isotopically enriched compounds have structures depicted by the general formula given herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Exemplary isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 18 F. 32 P. 35 S. 36 Cl and 125 I.
[0212] In another aspect, the compounds of the invention include isotopically enriched compounds as defined herein, for example, wherein a radioactive isotope is present, such as 3 H. 14 C and 18 Those compounds of F, or in which non-radioactive isotopes are present, such as 2 H and 13 C. This type of isotope-enriched compound can be used for metabolic studies (using 14 C), reaction kinetics studies (using e.g. 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution determination, or may be used in the context of radiotherapy of patients. 18 F-enriched compounds are particularly ideal for PET or SPECT studies. Isotopically enriched compounds of formula (I) can be prepared by conventional techniques familiar to those skilled in the art or by replacing the previously used unlabeled reagent with an appropriate isotopically labeled reagent as described in the examples and preparations herein.
[0213] In addition, heavier isotopes, particularly deuterium (i.e. 2 Substitution with H or D) can provide certain therapeutic advantages resulting from greater metabolic stability. For example, this can result in an increased in vivo half-life, a reduced dosage requirement, or an improved therapeutic index. It should be understood that deuterium in the present invention is considered a substituent of the compound of formula (I). The concentration of such heavier isotopes, particularly deuterium, can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" refers to the ratio between the isotopic abundance and the natural abundance of a given isotope. Where a substituent of a compound of the invention is designated as deuterium, the compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates according to the invention include those wherein the solvent of crystallization may be isotopically substituted, eg D2O, acetone-d6, DMSO-d6.
[0214] In another aspect, the present invention relates to intermediates for preparing compounds represented by formula (I).
[0215] In another aspect, the present invention relates to methods for preparing, separating and purifying the compound represented by formula (I).
[0216] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention. In some embodiments, the pharmaceutical composition further comprises at least one of a pharmaceutically acceptable excipient, vehicle, carrier, or vehicle. In other embodiments, the pharmaceutical composition may be in the form of a liquid, solid, semisolid, gel, or spray.
[0217] In another aspect, the present invention relates to a method for treating a disease or disorder regulated by a JAK, the method comprising administering to a mammal an effective amount of a compound or pharmaceutical composition disclosed herein. In some embodiments, the JAK is TYK2. In some embodiments, the disease or disorder is selected from multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome, or scleroderma.
[0218] In another aspect, the present invention relates to the use of the compounds or pharmaceutical compositions disclosed herein for treating a disease or disorder selected from multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome, or scleroderma.
[0219] In another aspect, the present invention relates to the use of the compounds or pharmaceutical compositions disclosed herein in the preparation of a medicament for treating a disease or disorder selected from multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome or scleroderma.
[0220] In another aspect, the present invention relates to the use of the compound or pharmaceutical composition disclosed in the present invention for preparing a medicament for inhibiting the activity of TYK2.
[0221] Pharmaceutical compositions, formulations and administration of the compounds of the present invention
[0222] The present invention provides a pharmaceutical composition comprising a compound disclosed herein, or a compound listed in the Examples, and at least one of a pharmaceutically acceptable excipient, vehicle, carrier, or solvent. The amount of compound in the pharmaceutical composition disclosed herein is an amount effective to detectably inhibit protein kinase in a biological sample or patient.
[0223] It should also be recognized that certain compounds of the present invention may be used therapeutically in free form or, if appropriate, in the form of pharmaceutically acceptable derivatives thereof. Some non-limiting embodiments of pharmaceutically acceptable derivatives include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adducts or derivatives that, when administered to a patient in need thereof, directly or indirectly provide a compound of the present invention or a metabolite or residue thereof.
[0224] The pharmaceutical compositions disclosed herein can be prepared and packaged in bulk form, wherein a safe and effective amount of the compound of formula (I) can be extracted and then administered to a patient in the form of a powder or syrup. Alternatively, the pharmaceutical compositions disclosed herein can be prepared and packaged in unit dosage form, wherein each physically discrete unit contains a safe and effective amount of the compound of formula (I).
[0225] As used herein, "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, mixture, or vehicle that contributes to the consistency of a dosage form or pharmaceutical composition. Each excipient, when combined, must be compatible with the other ingredients of the pharmaceutical composition to avoid interactions that could significantly reduce the efficacy of the disclosed compounds upon administration to a patient and interactions that could render the pharmaceutical composition unpharmaceutically acceptable. Furthermore, each excipient must be pharmaceutically acceptable, e.g., possess a sufficiently high degree of purity.
[0226] Suitable pharmaceutically acceptable excipients will vary depending on the specific dosage form selected. In addition, pharmaceutically acceptable excipients may be selected based on their specific function in the composition. For example, certain pharmaceutically acceptable excipients may be selected to facilitate the production of a uniform dosage form. Certain pharmaceutically acceptable excipients may be selected to facilitate the production of a stable dosage form. Certain pharmaceutically acceptable excipients may be selected to facilitate the transport or transportation of the disclosed compounds from one organ or part of the body to another organ or part of the body when administered to a patient. Certain pharmaceutically acceptable excipients may be selected to enhance patient compliance.
[0227] Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, cosolvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. It will be appreciated by those skilled in the art that certain pharmaceutically acceptable excipients may provide more than one function and may provide alternative functions, depending on how much of the excipient is present in the formulation and which other excipients are present in the formulation.
[0228] The skilled person has the knowledge and skill in this area to enable them to select a suitable pharmaceutically acceptable excipient for the appropriate amount of the present invention. In addition, there are a large number of resources available to the skilled person that describe pharmaceutically acceptable excipients and are used to select suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
[0229] Various carriers for preparing pharmaceutically acceptable compositions and known techniques for their preparation are disclosed in Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D. B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York, the contents of each of which are incorporated herein by reference. Except for any conventional carriers that are incompatible with the disclosed compounds, such as those that may produce any undesirable biological effects or that may interact in a deleterious manner with any other ingredient in the pharmaceutically acceptable composition, it is contemplated that their use is within the scope of the present invention.
[0230] The pharmaceutical compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. A description of some common methods in the art can be found in Remington's Pharmaceutical Sciences (Mack Publishing Company).
[0231] Thus, in another aspect, the present invention relates to a process for preparing a pharmaceutical composition comprising a compound disclosed herein and at least one of a pharmaceutically acceptable excipient, vehicle, carrier, or vehicle, the process comprising mixing the ingredients. The pharmaceutical composition comprising a compound disclosed herein can be prepared by mixing at, for example, ambient temperature and atmospheric pressure.
[0232] The compounds disclosed herein are generally formulated into dosage forms suitable for administration to a patient via a desired route. For example, dosage forms include those suitable for the following routes of administration: (1) oral administration, such as tablets, capsules, caplets, pills, lozenges, powders, syrups, elixirs, suspensions, solutions, emulsions, granules, and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and lyophilized powders; (3) transdermal administration, such as transdermal patches; (4) rectal administration, such as suppositories; (5) inhalation administration, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
[0233] In some embodiments, the compounds disclosed herein can be formulated into oral dosage forms. In other embodiments, the compounds disclosed herein can be formulated into inhalation dosage forms. In other embodiments, the compounds disclosed herein can be formulated into nasal dosage forms. In yet other embodiments, the compounds disclosed herein can be formulated into transdermal dosage forms. In still other embodiments, the compounds disclosed herein can be formulated into topical dosage forms.
[0234] The pharmaceutical compositions provided herein can be provided as compressed tablets, tablets, chewable lozenges, fast-dissolving tablets, composite compressed tablets, or enteric-coated, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with a substance that resists the effects of gastric acid but dissolves or disintegrates in the intestines, thereby protecting the active ingredients from the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which helps mask unpleasant tastes or odors and prevents tablet oxidation. Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble substance. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coatings impart the same general properties as sugar coatings. Composite compressed tablets are compressed tablets produced through more than one compression cycle, including multilayer tablets and press-coated or dry-coated tablets.
[0235] Tablet dosage forms can be prepared from the active ingredient in powder, crystal or granular form alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled release polymers, lubricants, diluents and / or colorants. Flavoring agents and sweeteners are particularly useful in forming chewable tablets and lozenges.
[0236] The pharmaceutical composition provided by the present invention can be provided in soft capsules or hard capsules, which can be prepared from gelatin, methylcellulose, starch or calcium alginate. The hard gelatin capsule, also known as dry-filled capsule (DFC), consists of two sections, one section inserted into the other, thus completely encapsulating the active ingredient. Soft elastic capsules (SEC) are soft, spherical shells, such as gelatin shells, which are plasticized by adding glycerol, sorbitol or similar polyols. The soft gelatin shells can contain preservatives to prevent microbial growth. Suitable preservatives are those as described in the present invention, including methylparaben and propylparaben, and sorbic acid. The liquid, semisolid and solid dosage forms provided by the present invention can be encapsulated in capsules. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239 and 4,410,545. The capsules may also be coated as known to those skilled in the art to improve or sustain dissolution of the active ingredient.
[0237] The pharmaceutical compositions provided herein can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. Emulsions are two-phase systems in which one liquid is completely dispersed in another liquid in the form of small globules, which can be oil-in-water or water-in-oil. Emulsions can include pharmaceutically acceptable non-aqueous liquids and solvents, emulsifiers, and preservatives. Suspensions can include pharmaceutically acceptable suspending agents and preservatives. Aqueous alcoholic solutions can include pharmaceutically acceptable acetals, such as di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal; and water-soluble solvents having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweet-tasting hydroalcoholic solutions. Syrups are concentrated aqueous solutions of sugars, such as sucrose, and can also contain preservatives. For liquid dosage forms, for example, solutions in polyethylene glycol can be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier, such as water, for accurate and convenient administration.
[0238] Other useful liquid and semisolid dosage forms include, but are not limited to, those comprising the active ingredient provided herein and a secondary mono- or poly-alkylene glycol, including 1,2-dimethoxymethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol dimethyl ether, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These formulations may further include one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters and dithiocarbamates.
[0239] Where appropriate, dosage unit formulations for oral administration can be microencapsulated.Delayed or sustained-release compositions can also be prepared, for example, by coating or embedding particulate material in polymers, wax, or the like.
[0240] The oral pharmaceutical composition provided by the present invention can also be provided in the form of liposomes, micelles, microspheres or nanosystems. Micellar dosage forms can be prepared using the method described in US Pat. No. 6,350,458.
[0241] The pharmaceutical compositions provided herein can be provided in non-effervescent or effervescent granules and powders for reconstitution into liquid dosage forms. Pharmaceutically acceptable carriers and excipients used in non-effervescent granules or powders can include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in effervescent granules or powders can include organic acids and carbon dioxide sources.
[0242] Coloring and flavoring agents can be used in all of the above dosage forms.
[0243] The compounds disclosed herein can also be combined with soluble polymers as targeted drug carriers. Such polymers include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethylene glycol polylysine substituted with palmitoyl residues. In addition, the compounds disclosed herein can be combined with a class of biodegradable polymers used in achieving controlled release of drugs, such as crosslinked or amphiphilic block copolymers of polylactic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels.
[0244] The pharmaceutical composition provided by the present invention can be co-formulated with other active ingredients that do not impair the intended therapeutic effect, or co-formulated with substances that supplement the intended effect.
[0245] Pharmaceutical composition provided by the invention can be administered parenterally by injection, infusion or implantation, for local or systemic administration. Parenteral administration as used in the present invention includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous administration.
[0246] Pharmaceutical composition provided by the invention can be mixed with any dosage form suitable for parenteral administration, including solution, suspension, emulsion, micelle, liposome, microsphere, nanometer system and the solid form that is suitable for making solution or suspension in liquid before injection.Such dosage form can be prepared (referring to Remington:The Science and Practice of Pharmacy, the same) according to conventional method known to those skilled in the art of pharmaceutical science.
[0247] Pharmaceutical compositions intended for parenteral administration may include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous carriers, water-miscible carriers, non-aqueous carriers, antimicrobial agents or preservatives against microbial growth, stabilizers, solubility enhancers, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, antifreezes, cryoprotectants, thickeners, pH adjusters, and inert gases.
[0248] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose, and lactated Ringers injection. Non-aqueous vehicles include, but are not limited to, fixed oils of plant origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, medium-chain triglycerides of hydrogenated soybean oil and coconut oil, and palm seed oil. Water-miscible vehicles include, but are not limited to, ethanol, 1,3-butylene glycol, liquid polyethylene glycols (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerol, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
[0249] Suitable antimicrobial agents or preservatives include, but are not limited to, phenol, cresol, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl parabens, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl and propyl parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerol, and dextrose. Suitable buffers include, but are not limited to, phosphates and citrates. Suitable antioxidants are those described herein, including bisulfites and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those described herein, including sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifiers include those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestrants or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, and sulfobutyl ether 7-β-cyclodextrin ( CyDex, Lenexa, KS).
[0250] The pharmaceutical compositions provided herein can be formulated for single or multiple dose administration. The single dose formulations are packaged in ampoules, vials, or syringes. The multiple dose parenteral formulations must contain an antimicrobial agent at a bacteriostatic or fungistatic concentration. All parenteral formulations must be sterile, as known and practiced in the art.
[0251] In some embodiments, the pharmaceutical composition is provided as a ready-to-use sterile solution. In other embodiments, the pharmaceutical composition is provided as a sterile dry soluble product, including lyophilized powders and subcutaneous tablets, which are reconstituted with a vehicle prior to use. In yet other embodiments, the pharmaceutical composition is formulated as a ready-to-use sterile suspension. In yet other embodiments, the pharmaceutical composition is formulated as a sterile dry insoluble product that is reconstituted with a vehicle prior to use. In still other embodiments, the pharmaceutical composition is formulated as a ready-to-use sterile emulsion.
[0252] Suitable inner matrices include polymethyl methacrylate, polybutyl methyl acrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic acid and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
[0253] Suitable outer polymeric films include polyethylene, polypropylene, ethylene / propylene copolymers, ethylene / ethyl acrylate copolymers, ethylene / vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, neoprene, chlorinated polyethylene, polyvinyl chloride, copolymers of chlorinated ethylene and vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene / vinyl alcohol copolymers, ethylene / vinyl acetate / vinyl alcohol terpolymers, and ethylene / vinyloxyethanol copolymers.
[0254] On the other hand, the pharmaceutical compositions disclosed herein can be formulated into any dosage form suitable for inhalation administration to a patient, such as a dry powder, an aerosol, a suspension or a solution composition. In some embodiments, the pharmaceutical compositions disclosed herein can be formulated into a dosage form suitable for inhalation administration to a patient using a dry powder. In yet other embodiments, the pharmaceutical compositions disclosed herein can be formulated into a dosage form suitable for inhalation administration to a patient via a nebulizer. Dry powder compositions delivered to the lungs by inhalation typically comprise a fine powder of the compound disclosed herein and one or more fine powdered pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients particularly suitable for use as dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di- and polysaccharides. Fine powders can be prepared, for example, by micronization and grinding. In general, size-reduced (e.g., micronized) compounds can be prepared by a D 50 values (e.g., measured by laser diffraction).
[0255] Aerosols can be prepared by suspending or dissolving the compounds disclosed herein in a liquefied propellant. Suitable propellants include chlorinated hydrocarbons, hydrocarbons, and other liquefied gases. Representative propellants include: trichlorofluoromethane (propellant 11), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetrafluoroethane (HFA-134a), 1,1-difluoroethane (HFA-152a), difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptafluoropropane (HFA-227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane, and pentane. Aerosols containing the compounds disclosed herein are typically administered to patients via a metered dose inhaler (MDI). Such devices are known to those skilled in the art.
[0256] Aerosols may contain additional pharmaceutically acceptable excipients that can be used with MDIs, such as surfactants, lubricants, co-solvents, and other excipients to improve the physical stability of the formulation, improve valve characteristics, improve solubility, or improve taste.
[0257] Pharmaceutical compositions suitable for transdermal administration can be prepared as discontinuous patches intended to remain in close contact with the patient's epidermis for an extended period of time. For example, the active ingredient can be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
[0258] The pharmaceutical composition that is suitable for topical administration can be formulated into ointment, cream, suspension, lotion, powder, solution, paste, gel, spray, aerosol or oil.For example, ointment, cream and gel can be prepared with water or oil base, and applicable thickener and / or gel and / or solvent.Such matrix can comprise, water, and / or oil such as liquid paraffin and vegetable oil (such as peanut oil or castor oil), or solvent such as polyethylene glycol.The thickener and gel that use according to matrix properties comprise soft paraffin, aluminum stearate, cetearyl alcohol, polyethylene glycol, lanolin, beeswax, carboxyvinyl polyol and cellulose derivative, and / or glyceryl monostearate and / or nonionic emulsifier.
[0259] Lotions may be formulated with an aqueous or oily base, and generally also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents or thickening agents.
[0260] Powders for external use may be formulated in the presence of any suitable powder base such as talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base containing one or more dispersants, solubilizers, suspending agents or preservatives.
[0261] Topical formulations can be administered by application to the affected area once or more daily; occlusive dressings covering the skin are preferred. Adhesive reservoir systems allow for continuous or prolonged administration.
[0262] For treatment of the eye, or other organs such as the mouth and skin, the compositions can be applied as a topical ointment or cream. When formulated as an ointment, the compounds disclosed herein can be used with either a paraffinic or a water-soluble ointment base. Alternatively, the compounds disclosed herein can be formulated into a cream with an oil-in-water cream base or an oil-in-water base.
[0263] In some embodiments, the treatment methods disclosed herein include administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising the compound of the present invention to a patient in need thereof. Various embodiments disclosed herein include methods for treating the above-mentioned diseases by administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising the compound of the present invention to a patient in need thereof.
[0264] In some embodiments, the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein can be administered by any suitable route of administration, including systemic administration and topical administration. Systemic administration includes oral administration, parenteral administration, transdermal administration, and rectal administration. Typical parenteral administration refers to administration by injection or infusion, including intravenous, intramuscular, and subcutaneous injection or infusion. Topical administration includes application to the skin, as well as intraocular, ear, vaginal, inhalation, and intranasal administration. In one embodiment, the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein can be orally administered. In other embodiments, the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein can be inhaled. In another embodiment, the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein can be intranasally administered.
[0265] In some embodiments, the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein can be administered once, or several times at different time intervals within a specified time period according to a dosing regimen. For example, the drug is administered once, twice, three times, or four times a day. In some embodiments, the drug is administered once a day. In yet other embodiments, the drug is administered twice a day. The drug can be administered until the desired therapeutic effect is achieved or the desired therapeutic effect is maintained indefinitely. The appropriate dosing regimen for the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein depends on the pharmacokinetic properties of the compound, such as absorption, distribution, and half-life, which can be determined by a technician. In addition, the appropriate dosing regimen for the compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein, including the duration of implementation of the regimen, depends on the disease being treated, the severity of the disease being treated, the age and physical condition of the patient being treated, the medical history of the patient being treated, the nature of the concurrent therapy, the desired therapeutic effect, and other factors within the knowledge and experience of the technician. Such technicians should also understand that the appropriate dosing regimen may be required to be adjusted for individual patients' response to the dosing regimen, or when individual patient needs change over time.
[0266] The compounds disclosed herein can be administered simultaneously with, before, or after one or more other therapeutic agents. The compounds disclosed herein can be administered separately with other therapeutic agents via the same or different routes of administration, or in the form of the same pharmaceutical composition.
[0267] For individuals weighing about 50-70 kg, the pharmaceutical compositions and combinations disclosed herein can be in unit dosage forms containing about 1-1000 mg, or about 1-500 mg, of the active ingredient. The therapeutically effective amount of the compound, pharmaceutical composition, or combination thereof depends on the species, weight, age, and individual condition of the individual being administered, the disorder or disease being treated, or its severity. A physician, clinician, or veterinarian with common skills can readily determine the effective amount of each active ingredient required to prevent, treat, or inhibit the progression of a disorder or disease.
[0268] The dosage characteristics cited above have been demonstrated in vitro and in vivo using advantageous mammals (e.g., mice, rats, dogs, monkeys) or isolated organs, tissues, and specimens thereof. The compounds disclosed herein are administered in vitro in the form of solutions, e.g., aqueous solutions, and in vivo in the form of suspensions or aqueous solutions, either enterally, parenterally, or particularly intravenously.
[0269] In some embodiments, a therapeutically effective dose of a compound disclosed herein is from about 0.1 mg to about 2,000 mg per day. A pharmaceutical composition thereof should provide a dose of about 0.1 mg to about 2,000 mg of the compound. In a specific embodiment, a pharmaceutical dosage unit form is prepared that provides from about 1 mg to about 2,000 mg, from about 10 mg to about 1,000 mg of the active ingredient, or a combination of the active ingredients per dosage unit form.
[0270] In addition, the compounds disclosed in the present invention can be administered in the form of prodrugs. In the present invention, the "prodrug" of the compounds disclosed in the present invention is a functional derivative that can ultimately release the compounds disclosed in the present invention in vivo when administered to a patient. When administering the compounds disclosed in the present invention in the form of prodrugs, those skilled in the art may implement one or more of the following methods: (a) changing the onset time of the compound in vivo; (b) changing the duration of the compound's action in vivo; (c) changing the compound's transport or distribution in vivo; (d) changing the compound's solubility in vivo; and (e) overcoming the side effects or other difficulties faced by the compound. Typical functional derivatives used to prepare prodrugs include variants of the compound that are chemically or enzymatically cleaved in vivo. These variants, including those for preparing phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
[0271] Uses of the compounds and pharmaceutical compositions of the present invention
[0272] The present invention provides compounds and pharmaceutical compositions disclosed herein for treating, preventing or ameliorating diseases or disorders mediated by or otherwise affected by TYK2, particularly for preparing medicaments for treating, preventing or ameliorating viral diseases, genetic diseases, inflammatory diseases or autoimmune diseases.
[0273] Specifically, the present invention provides a class of compounds disclosed herein or pharmaceutical compositions comprising the compounds disclosed herein for treating, preventing or ameliorating diseases or disorders mediated or otherwise affected by inappropriate TYK2 behavior, or diseases or disorders mediated or otherwise affected by inappropriate TYK2 behavior, wherein the diseases or disorders are selected from viral diseases, genetic diseases, inflammatory diseases or autoimmune diseases.
[0274] In some embodiments, such diseases or disorders include, but are not limited to, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Sjögren's syndrome, or scleroderma.
[0275] In another aspect, the present invention provides a method for treating a mammal suffering from or at risk of suffering from a disease disclosed herein, comprising administering a therapeutically effective dose or a prophylactically effective dose of one or more pharmaceutical compositions or compounds disclosed herein.
[0276] In one method of treatment, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from a disease mediated by TYK2, the method comprising administering a therapeutically effective or prophylactically effective dose of one or more pharmaceutical compositions or compounds disclosed herein. In particular embodiments, the disease mediated by TYK2 is selected from a viral disease, a genetic disease, an inflammatory disease, or an autoimmune disease.
[0277] In another aspect, the present invention provides a class of compounds disclosed herein, or pharmaceutical compositions comprising the compounds disclosed herein, for use in the preparation of a medicament for treating or preventing a disease mediated by TYK2. In certain embodiments, the disease mediated by TYK2 is selected from a viral disease, a genetic disease, an inflammatory disease, or an autoimmune disease.
[0278] In another aspect, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from a viral disease, a genetic disease, an inflammatory disease, or an autoimmune disease, the method comprising administering an effective therapeutic amount or an effective prophylactic amount of one or more pharmaceutical compositions or compounds disclosed herein. In a specific embodiment, the inflammatory disease is selected from, but not limited to, Crohn's disease and ulcerative colitis; the autoimmune disease is selected from, but not limited to, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Sjögren's syndrome, or scleroderma.
[0279] General synthetic steps
[0280] To illustrate the present invention, the following examples are listed. However, it should be understood that the present invention is not limited to these examples, which are only provided to provide methods for practicing the present invention.
[0281] Generally, the compounds of the present invention can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are defined as shown in formula (I). The following reaction schemes and examples are provided to further illustrate the present invention.
[0282] Those skilled in the art will recognize that the chemical reactions described herein can be used to appropriately prepare many other compounds of the present invention, and that other methods for preparing the compounds of the present invention are considered to be within the scope of the present invention. For example, the synthesis of non-exemplified compounds according to the present invention can be successfully accomplished by those skilled in the art through modifications such as appropriate protection of interfering groups, by utilizing other known reagents in addition to those described herein, or by making conventional modifications to the reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also generally applicable to the preparation of other compounds of the present invention.
[0283] In the examples described below, all temperatures are set forth in degrees Celsius unless otherwise indicated. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company, and Alfa Chemical Company and used without further purification unless otherwise indicated. Common reagents were purchased from Shantou Xilong Chemical Plant, Guangdong Guanghua Chemical Reagent Plant, Guangzhou Chemical Reagent Plant, Tianjin Haoyuyu Chemical Co., Ltd., Tianjin Fuchen Chemical Reagent Plant, Wuhan Xinhuayuan Technology Development Co., Ltd., Qingdao Tenglong Chemical Reagent Co., Ltd., and Qingdao Ocean Chemical Plant.
[0284] Anhydrous tetrahydrofuran, dioxane, toluene, and diethyl ether were dried over sodium reflux. Anhydrous dichloromethane and chloroform were dried over calcium hydride reflux. Ethyl acetate, petroleum ether, n-hexane, N,N-dimethylacetamide, and N,N-dimethylformamide were dried over anhydrous sodium sulfate before use.
[0285] The following reactions were generally carried out under a positive pressure of nitrogen or argon or with a drying tube over anhydrous solvents (unless otherwise indicated), reaction flasks were plugged with suitable rubber stoppers, and substrates were introduced via syringe. All glassware was dried.
[0286] The chromatographic column used was a silica gel column. Silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Plant.
[0287] 1 H NMR spectra were recorded using a Bruker 400 MHz or 600 MHz nuclear magnetic resonance spectrometer. 1 H NMR spectra were obtained in CDC13, D2O, DMSO-d6, CD3OD, or acetone-d6 solvents (in ppm), using TMS (0 ppm) or chloroform (7.26 ppm) as the reference standard. When multiple peaks are present, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), ddd (doublet of doublet of doublets), dddd (doublet of doublet of doublets), dt (doublet of triplets), and tt (triplet of triplets). Coupling constants, J, are expressed in Hertz (Hz).
[0288] Low-resolution mass spectrometry (MS) data were obtained using an Agilent 6120 quadrupole HPLC-M column (Zorbax SB-C18 column, 2.1 × 30 mm, 3.5 μm, 6 min, and a flow rate of 0.6 mL / min. Mobile phase was a 5% to 95% ratio of CH3CN containing 0.1% formic acid in H2O containing 0.1% formic acid), using electrospray ionization (ESI) at 210 nm / 254 nm with UV detection.
[0289] Pure compounds were analyzed using Agilent 1260 pre-HPLC or Calesep pump 250 pre-HPLC (column model: NOVASEP 50 / 80 mm DAC) with UV detection at 210 nm / 254 nm.
[0290] The following abbreviations are used throughout this invention:
[0291] The following reaction schemes describe the steps for preparing the compounds of the present invention. 1 、R 2 , A1, A2, A3, X, Y, V1, V2, V3, V4, V5 and V6 have the definitions as described in the present invention.
[0292] Synthesis Scheme 1
[0293] The compound represented by formula (7) can be prepared by synthetic scheme 1: the compound represented by formula (1) reacts with sodium methyl mercaptan to obtain the compound represented by formula (2). The compound represented by formula (2) and the compound represented by formula (3) undergo a Suzuki reaction in the presence of a palladium catalyst to obtain the compound represented by formula (4). The compound represented by formula (4) reacts with the compound represented by formula (5) to obtain the compound represented by formula (6). The compound represented by formula (6) undergoes an oxidation reaction to obtain the compound represented by formula (7).
[0294] Synthesis Scheme 2
[0295] The compound represented by formula (12) can be prepared by synthetic scheme 2: the compound represented by formula (8) reacts with sodium methyl mercaptan to obtain the compound represented by formula (9). The compound represented by formula (9) and the compound represented by formula (3) undergo a Suzuki reaction in the presence of a palladium catalyst to obtain the compound represented by formula (10). The compound represented by formula (10) reacts with the compound represented by formula (5) to obtain the compound represented by formula (11). The compound represented by formula (11) undergoes an oxidation reaction to obtain the compound represented by formula (12).
[0296] Synthesis Scheme 3
[0297] The compound represented by formula (17) can be prepared by synthetic scheme 3: the compound represented by formula (13) reacts with sodium methyl mercaptan to obtain the compound represented by formula (14). The compound represented by formula (14) and the compound represented by formula (3) undergo a Suzuki reaction in the presence of a palladium catalyst to obtain the compound represented by formula (15). The compound represented by formula (15) reacts with the compound represented by formula (5) to obtain the compound represented by formula (16). The compound represented by formula (16) undergoes an oxidation reaction to obtain the compound represented by formula (17).
[0298] The following examples further illustrate the compounds, pharmaceutical compositions, and applications of the present invention. In the case of discrepancies between the names and structures of the compounds described in the present invention, the structures shall prevail. Example
[0299] Synthesis of Fragment 5-Acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic Acid Tert-Butyl Ester
[0300] Prepared by referring to the synthetic method of steps 1-2 of Example 37 in patent application WO2022033544.
[0301] Example 1 N-(1-methyl-3-(6-(methylsulfonyl)-[1,3]dioxolo[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0302] Step 1: Synthesis of 2-bromo-6-iodo-3-methoxypyridine
[0303] To a reaction flask, add 2-bromo-6-iodo-3-hydroxypyridine (8.0 g, 26.68 mmol), potassium carbonate (5.53 g, 40.02 mmol), and N,N-dimethylformamide (80 mL). Methyl iodide (4.92 g, 34.68 mmol) was added while stirring at room temperature. The mixture was then heated to 30°C and stirred for 3.0 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to afford the product as a white solid (7.91 g, 94.46% yield).
[0304] MS (ESI, pos.ion) m / z: 313.9 [M+H] + ;
[0305] 1H NMR (400MHz, CDCl3) δ7.59 (d, J = 8.3Hz, 1H), 6.84 (d, J = 8.3Hz, 1H), 3.89 (s, 3H).
[0306] Step 2: Synthesis of 2-bromo-6-iodo-3-methoxypyridin-4-ol
[0307] 2-Bromo-6-iodo-3-methoxypyridine (10.90 g, 34.72 mmol) and anhydrous tetrahydrofuran (180 mL) were added to the reaction flask. Under nitrogen protection, the reaction system was stirred at -78 ° C for 20 min. A solution of lithium diisopropylamide in tetrahydrofuran (26.04 mL, 52.08 mmol, 2.0 M) was added dropwise. After the addition was completed, the reaction was kept warm for about 1.0 h, and trimethyl borate (5.41 g, 52.08 mmol) was added. After stirring at low temperature for about 3.0 h, the reaction system was heated to -60 ° C. , hydrogen peroxide (7.09 mL, 69.44 mmol, 30 wt %) was added dropwise, and after completion of the addition, the mixture was transferred to room temperature and stirred overnight. Saturated aqueous sodium thiosulfate solution (26.0 mL) was added to quench the reaction, and the pH was adjusted to 7 with dilute hydrochloric acid (1.0 M). The liquids were separated, and the aqueous phase was extracted with ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 2 / 1) to give a yellow solid product (5.87 g, yield 51.24%).
[0308] MS (ESI, pos.ion) m / z: 330.3 [M+H] + ;
[0309] 1 H NMR (400MHz, DMSO-d6) δ11.69(s,1H),7.23(s,1H),3.75(s,3H).
[0310] Step 3: Synthesis of 2-bromo-6-iodopyridine-3,4-diol
[0311] 2-Bromo-6-iodo-3-methoxypyridin-4-ol (5.82 g, 17.64 mmol) and dichloromethane (100 mL) were added to the reaction flask. Under nitrogen protection, the mixture was stirred at 0°C, and boron tribromide (11.90 mL, 123.48 mmol) was added dropwise. The mixture was transferred to room temperature and stirred for 6.0 h. Anhydrous methanol (100 mL) was slowly added to quench the reaction. The suspension was filtered and the filter cake was dried to give a white solid product (4.89 g, yield 87.75%).
[0312] MS (ESI, pos.ion) m / z: 315.8 [M+H] + ;
[0313] 1 H NMR(400MHz,DMSO-d6)δ7.13(s,1H).
[0314] Step 4: Synthesis of 4-bromo-6-iodo-[1,3]dioxolo[4,5-c]pyridine
[0315] 2-Bromo-6-iodopyridine-3,4-diol (4.0 g, 12.66 mmol), cesium carbonate (12.37 g, 37.98 mmol), chloroiodomethane (3.35 g, 18.99 mmol) and N,N-dimethylformamide (35.0 mL) were added to the reaction flask, the reaction system was heated to 100 ° C and stirred for 5.0 h, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 50 / 1) to give a white solid product (1.25 g, yield 30.11%).
[0316] MS (ESI, pos.ion) m / z: 328.0 [M+H] + ;
[0317] 1 H NMR (400MHz, CDCl3) δ7.17(s,1H),6.13(s,2H).
[0318] Step 5: Synthesis of 4-bromo-6-(methylthio)-[1,3]dioxolo[4,5-c]pyridine
[0319] 4-Bromo-6-iodo-[1,3]dioxolo[4,5-c]pyridine (600 mg, 1.83 mmol), sodium thiomethoxide (140 mg, 2.00 mmol), trisdibenzylideneacetone dipalladium (84 mg, 0.092 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (110 mg, 0.18 mmol) and 1,4-dioxane (35.0 mL) were added to the reaction flask. After nitrogen ventilation, the temperature was raised to 100 ° C. and stirred for 6.0 h. The mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give a white solid product (208 mg, yield 45.82%).
[0320] MS (ESI, pos.ion) m / z: 248.0 [M+H] + ;
[0321] 1 H NMR (400MHz, CDCl3) δ6.66(s,1H),6.07(s,2H),2.53(s,3H).
[0322] Step 6: Synthesis of N-(3-(6-(methylthio)-[1,3]dioxolo[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0323] Add 4-bromo-6-(methylthio)-[1,3]dioxol[4,5-c]pyridine (187.0 mg, 0.75 mmol), 5-acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (330.0 mg, 0.83 mmol), and potassium carbonate (210.0 mg, 1.5 mmol) to the reaction flask. and PdCl2dppf-DCM (92.0 mg, 0.11 mmol), and then under nitrogen protection, 1,4-dioxane (10 mL) and water (4 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100 ° C, and stirred overnight, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a tan solid product (250.0 mg, yield 96.88%).
[0324] MS (ESI, pos.ion) m / z: 343.1 [M+H] + ;
[0325] 1 H NMR(400MHz,DMSO-d6)δ11.92(s,1H),10.16(s,1H),9.11(s,1H),8.54(s,1H ), 8.10 (d, J = 2.4Hz, 1H), 6.84 (s, 1H), 6.23 (s, 2H), 2.71 (s, 3H), 2.08 (s, 3H).
[0326] Step 7: Synthesis of N-(1-methyl-3-(6-(methylthio)-[1,3]dioxolo[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0327] N-(3-(6-(methylthio)-[1,3]dioxol[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (250.0 mg, 0.73 mmol), cesium carbonate (310 mg, 0.95 mmol) and N,N-dimethylformamide (12.0 mL) were added to the reaction flask. Under stirring at room temperature, iodomethane (120 mg, 0.88 mmol) was added dropwise. The mixture was stirred at room temperature for 1.0 h. Water (1 mL) was added to quench the reaction. The system was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give a light yellow solid product (190 mg, yield 73.01%).
[0328] MS (ESI, pos.ion) m / z: 357.2 [M+H] + ;
[0329] 1 H NMR (400MHz, DMSO-d6) δ10.22(s,1H),9.11(s,1H),8.63(s,1H),8.06(s,1H),6.83(s,1H),6.23(s,2H),3.95(s,3H),2.71(s,3H),2.09(s,3H).
[0330] Step 8: Synthesis of N-(1-methyl-3-(6-(methylsulfonyl)-[1,3]dioxolo[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0331] N-(1-methyl-3-(6-(methylthio)-[1,3]dioxol[4,5-c]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (120.0 mg, 0.34 mmol), methanol (8.0 mL), tetrahydrofuran (8.0 mL) were added to the reaction flask, and Oxone (420.0 mg, 0.68 mmol) in water (8 mL) was added under stirring at room temperature. .0mL) solution, after the addition was complete, stirring was continued at room temperature for 2.0h, saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8, water (10mL) was added, the layers were separated, and the aqueous phase was extracted with dichloromethane (30mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give a light yellow solid product (70.0mg, yield 53.53%).
[0332] MS (ESI, pos.ion) m / z: 389.1 [M+H] + .
[0333] Example 2: N-(1-methyl-3-(7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0334] Step 1: Synthesis of 2-bromo-6-iodo-3-methoxypyridine
[0335] To a reaction flask, add 2-bromo-6-iodo-3-hydroxypyridine (1.50 g, 5.0 mmol), potassium carbonate (1.04 g, 7.50 mmol), and N,N-dimethylformamide (12.0 mL). Methyl iodide (922.6 mg, 6.50 mmol) was added with stirring at room temperature, and the mixture was heated to 30°C and stirred for 3.0 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to afford an off-white solid product (1.50 g, 95.53% yield).
[0336] MS (ESI, pos.ion) m / z: 314.1 [M+H] + ;
[0337] 1 H NMR (400MHz, CDCl3) δ7.62 (d, J = 8.3Hz, 1H), 6.87 (d, J = 8.3Hz, 1H), 3.92 (s, 3H).
[0338] Step 2: Synthesis of 2-bromo-6-iodo-3-methoxypyridin-4-ol
[0339] 2-Bromo-6-iodo-3-methoxypyridine (3.00 g, 9.56 mmol) and anhydrous tetrahydrofuran (50 mL) were added to the reaction flask. Under nitrogen protection, the reaction system was stirred at -78 °C, and lithium diisopropylamide (7.0 mL, 14.0 mmol, 2.0 M in) was added dropwise. THF), after the addition is complete, the reaction is kept warm for about 1.0h, trimethyl borate (1.49g, 14.34mmol) is added, and stirring at low temperature is continued for about 3.0h. The reaction system is warmed to -60°C, hydrogen peroxide (2.0mL, 19.58mmol, 30wt%) is added dropwise, and after the dropwise addition is completed, the reaction is transferred to room temperature and stirred overnight. A saturated aqueous sodium thiosulfate solution (8.0mL) is added to quench the reaction, and the pH is adjusted to 7 with dilute hydrochloric acid (1.0M). The liquids are separated, and the aqueous phase is extracted with ethyl acetate (50mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue is separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 2 / 1) to give a yellow solid product (1.55g, yield 49.16%).
[0340] MS (ESI, pos.ion) m / z: 330.0 [M+H] + ;
[0341] 1 H NMR (400MHz, DMSO-d6) δ11.69(s,1H),7.24(s,1H),3.75(s,3H).
[0342] Step 3: Synthesis of 2-bromo-6-iodopyridine-3,4-diol
[0343] 2-Bromo-6-iodo-3-methoxypyridin-4-ol (1.70 g, 5.15 mmol) and dichloromethane (30 mL) were added to the reaction flask. Under nitrogen protection, the mixture was stirred at 0°C, and boron tribromide (3.43 mL, 35.64 mmol) was added dropwise. The mixture was transferred to room temperature and stirred overnight. Anhydrous methanol (100 mL) was slowly added to quench the reaction. The mixture was concentrated under reduced pressure to obtain a crude brown solid product (1.63 g, yield 100%).
[0344] MS (ESI, pos.ion) m / z: 315.9 [M+H] + .
[0345] Step 4: Synthesis of 5-bromo-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0346] 2-Bromo-6-iodopyridine-3,4-diol (1.63 g, 5.15 mmol), potassium carbonate (3.56 g, 25.75 mmol), 1,2-dibromoethane (1.45 g, 7.73 mmol) and N,N-dimethylformamide (30 mL) were added to the reaction flask, the reaction system was heated to 100 ° C and stirred for 2.0 h, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a yellow solid product (296.0 mg, yield 16.81%).
[0347] MS (ESI, pos.ion) m / z: 342.0 [M+H] + ;
[0348] 1 H NMR (400MHz, CDCl3) δ7.20 (s, 1H), 4.41 (dd, J = 5.5, 2.3Hz, 2H), 4.36 (dd, J = 5.5, 2.5Hz, 2H).
[0349] Step 5: Synthesis of 5-bromo-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0350] 5-Bromo-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (20.0 mg, 0.06 mmol), sodium thiomethoxide (3.66 mg, 0.05 mmol), trisdibenzylideneacetone dipalladium (2.7 mg, 0.003 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (3.4 mg, 0.006 mmol) and 1,4-dioxane (1.5 mL) were added to the reaction flask. After nitrogen purification, the temperature was raised to 85° C. and stirred overnight. The mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a crude yellow solid product (7.0 mg, yield 45.66%).
[0351] MS (ESI, pos.ion) m / z: 262.2 [M+H] + ;
[0352] 1 H NMR (400MHz, CDCl3) δ6.68(s,1H),4.40–4.36(m,2H),4.36–4.31(m,2H),2.53(s,3H).
[0353] Step 6: Synthesis of N-(3-(7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0354] Add 5-bromo-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (139.0 mg, 0.53 mmol), 5-acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (220.0 mg, 0.56 mmol), potassium carbonate (150.0 mg, 1.06 mmol) to the reaction flask. ), PdCl2dppf-DCM (43.0 mg, 0.05 mmol), then under nitrogen protection, 1,4-dioxane (5.0 mL) and water (2.0 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a crude yellow solid product (153.0 mg, yield 80.95%).
[0355] MS (ESI, pos.ion) m / z: 357.2 [M+H] + .
[0356] Step 7: Synthesis of N-(1-methyl-3-(7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0357] To the reaction flask were added N-(3-(7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (153.0 mg, 0.43 mmol), cesium carbonate (168.1 mg, 0.52 mmol) and N,N-dimethylformamide (3.0 mL). Under stirring at room temperature, iodomethane (68.1 mg, 0.48 mmol) was added dropwise. The mixture was stirred at room temperature for 2.5 h and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a crude yellow solid product (39.5 mg, yield 24.84%).
[0358] MS (ESI, pos.ion) m / z: 371.4 [M+H] + .
[0359] Step 8: Synthesis of N-(1-methyl-3-(7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0360] N-(1-methyl-3-(7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (79.0 mg, 0.11 mmol), methanol (3.0 mL), tetrahydrofuran (3.0 mL) and water (1.5 mL) were added to the reaction flask. Oxone (131.1 mg, 0 .21mmol), continued stirring at room temperature for about 1.5h, added saturated sodium bicarbonate aqueous solution to adjust pH=7-8, added water (10mL), separated, the aqueous phase was extracted with dichloromethane (40mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v)=30 / 1) to give a yellow solid product (20.0mg, yield 46.61%).
[0361] MS (ESI, pos.ion) m / z: 403.0 [M+H] + ;
[0362] 1H NMR(400MHz,DMSO-d6)δ10.30(s,1H),9.18(s,1H),8.65(s,1H),8.42(s,1H), 7.31(s,1H),4.56(s,2H),4.50(s,2H),3.96(s,3H),3.53(s,3H),2.11(s,3H).
[0363] Example 3: N-(1-methyl-3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0364] Step 1: Synthesis of 2,6-dibromo-4-methoxy-3-nitropyridine
[0365] 2,6-Dibromo-4-methoxypyridine (0.50 g, 1.87 mmol) and concentrated sulfuric acid (3.0 mL) were added to a reaction flask. Fuming nitric acid (0.16 mL, 3.16 mmol) was added with stirring at 0°C. After the addition, the reaction system was transferred to 100°C and reacted for 3.0 h. The reaction solution was slowly poured into ice water (10 mL), and ethyl acetate (50 mL) was added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (20 mL). The organic phases were combined, washed with water (20 mL x 3), dried over anhydrous sodium sulfate, and filtered to obtain the product as a yellow solid (509.0 mg, 87.11% yield).
[0366] 1 H NMR (400MHz, DMSO-d6) δ7.84 (s, 1H), 4.04 (s, 3H).
[0367] Step 2: Synthesis of 2,6-bromo-4-methoxypyridin-3-amine
[0368] To a reaction flask, 2,6-dibromo-4-methoxy-3-nitropyridine (0.50 g, 1.60 mmol), ethanol (10 mL), ammonium chloride (427.9 mg, 8.0 mmol), and iron powder (446.8 mg, 8.0 mmol) were added, followed by water (2.0 mL). The reaction system was heated to 90°C for 2.0 h. The mixture was cooled to room temperature and filtered. The filter cake was washed with a mixed solvent of dichloromethane / methanol (v / v = 10 / 1, 20 mL). The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to obtain the product as a white solid (451.9 mg, 100.0% yield).
[0369] MS (ESI, pos.ion) m / z: 280.8 [M+H]+ ;
[0370] 1 H NMR (400MHz, DMSO-d6) δ7.10(s,1H),5.14(s,2H),3.89(s,3H).
[0371] Step 3: Synthesis of 3-amino-2,6-dibromopyridin-4-ol
[0372] 2,6-Bromo-4-methoxypyridin-3-amine (500.0 mg, 1.77 mmol) and hydrobromic acid (7.0 mL) were added to the reaction flask, the reaction system was heated to 100 ° C and stirred for 3.0 h, cooled to room temperature, water (10 mL) and ethyl acetate (20 mL) were added, and then the pH was adjusted to 1-2 with saturated sodium bicarbonate solution under stirring. The layers were separated, and the aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give a gray solid product (434.0 mg, yield 91.34%).
[0373] MS (ESI, pos.ion) m / z: 267.0 [M+H] + ;
[0374] 1 H NMR (400MHz, DMSO-d6) δ11.47(s,1H),6.79(s,1H),4.93(s,2H).
[0375] Step 4: Synthesis of methyl 2-((3-amino-2,6-dibromopyridin-4-yl)oxy)acetate
[0376] To a reaction flask, 3-amino-2,6-dibromopyridin-4-ol (100.0 mg, 0.37 mmol), potassium iodide (61.0 mg, 0.37 mmol), potassium carbonate (61.0 mg, 0.44 mmol), and N,N-dimethylformamide (2.0 mL) were added. Methyl 2-chloroacetate (44.0 mg, 0.41 mmol) was added dropwise with stirring at room temperature. The mixture was allowed to react at room temperature for 4 h. Water (10 mL) and ethyl acetate (30 mL) were added, and the mixture was separated. The aqueous phase was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with water (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to afford the product as a yellow solid (98.0 mg, 77.23% yield).
[0377] MS (ESI, pos.ion) m / z: 339.0 [M+H]+ ;
[0378] 1 H NMR (400MHz, DMSO-d6) δ7.15(s,1H),5.16(s,2H),5.01(s,2H),3.72(s,3H).
[0379] Step 5: Synthesis of 5,7-dibromo-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one
[0380] Methyl 2-((3-amino-2,6-dibromopyridin-4-yl)oxy)acetate (93.0 mg, 0.27 mmol) and acetic acid (2.0 mL) were added to the reaction flask, the reaction system was heated to 100 ° C and stirred for 3.0 h, concentrated under reduced pressure, ethyl acetate (20 mL) was added, the liquid was separated, the organic phase was washed with water (5.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and the resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give an off-white solid product (50.0 mg, yield 59.36%).
[0381] MS (ESI, pos.ion) m / z: 307.0 [M+H] + ;
[0382] 1 H NMR (400MHz, CDCl3) δ7.03 (s, 1H), 4.67 (s, 2H).
[0383] Step 6: Synthesis of 5,7-dibromo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine
[0384] 5,7-Dibromo-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (100.0 mg, 0.32 mmol) and dry tetrahydrofuran (2.0 mL) were added to the reaction flask, followed by the addition of borane dimethyl sulfide complex (1.0 mL, 2.0 mmol, 2.0 M in THF). The reaction system was heated to 70 ° C and stirred for 5.0 h. Methanol (0.5 mL) was added to quench the reaction, and reflux was continued for 15 minutes. The temperature was cooled to room temperature and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give an off-white solid product (85.0 mg, yield 89.05%).
[0385] MS (ESI, pos.ion) m / z: 295.0 [M+H] + ;
[0386] 1H NMR (400MHz, CDCl3) δ6.84 (s, 1H), 4.30 (t, J = 4.0Hz, 2H), 4.26 (s, 1H), 3.53–3.48 (m, 2H).
[0387] Step 7: Synthesis of 5,7-dibromo-4-methyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine
[0388] To a reaction flask, 5,7-dibromo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (50.0 mg, 0.17 mmol) and N,N-dimethylformamide (3.0 mL) were added, along with sodium hydride (10.3 mg, 0.26 mmol, 60 wt%). Methyl iodide (42.3 mg, 0.30 mmol) was added while stirring at room temperature. The flask was sealed and the reaction system was heated to 80°C overnight. The product was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to afford an off-white solid (45.0 mg, 85.90% yield).
[0389] MS (ESI, pos.ion) m / z: 307.0 [M+H] + ;
[0390] 1 H NMR (400MHz, CDCl3) δ6.98 (s, 1H), 4.25 (t, J = 4.0Hz, 2H), 3.16 (t, J = 4.0Hz, 2H), 2.90 (s, 3H).
[0391] Step 8: Synthesis of 5-bromo-4-methyl-7-(methylthio)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine
[0392] 5,7-Dibromo-4-methyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (100.0 mg, 0.32 mmol), sodium thiomethoxide (24.7 mg, 0.35 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (37.0 mg, 0.06 mmol), tris(dibenzylideneacetone)dipalladium (29.3 mg, 0.03 mmol) and 1,4-dioxane (3.0 mL) were added to the reaction flask. The atmosphere was replaced with nitrogen, and the reaction system was heated to 100°C for overnight reaction. The reaction mixture was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give a yellow solid product (29.0 mg, yield 32.46%).
[0393] MS (ESI, pos.ion) m / z: 275.0 [M+H]+ ;
[0394] 1 H NMR (600MHz, CDCl3) δ6.66 (s, 1H), 4.23 (t, J = 4.0Hz, 2H), 3.15 (t, J = 4.0Hz, 2H), 2.87 (s, 3H), 2.52 (s, 3H).
[0395] Step 9: Synthesis of 5-bromo-4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine
[0396] 5-Bromo-4-methyl-7-(methylthio)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (30.0 mg, 0.11 mmol) and methanol (1.0 mL), tetrahydrofuran (1.0 mL) and water (0.5 mL) were added to the reaction flask, and the reaction system was stirred at room temperature for 2.5 h. Saturated sodium bicarbonate solution was slowly added to adjust the pH to 7-8. Water (10 mL) was added, and the liquids were separated. The aqueous phase was extracted with dichloromethane (40 mL×2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give a yellow solid product (21.0 mg, yield 62.71%).
[0397] MS (ESI, pos.ion) m / z: 307.3 [M+H] +
[0398] Step 10: Synthesis of tert-butyl 5-acetamide-3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate
[0399] In the reaction flask, 5-bromo-4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (69.0 mg, 0.22 mmol), 5-acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (90.1 mg, 0.22 mmol), potassium carbonate (61 mg, 0.4 4mmol) and PdCl2(dppf)-DCM (18.0mg, 0.02mmol), then under nitrogen protection, 1,4-dioxane (6.0mL) was added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C, and stirred overnight, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a crude yellow solid product (104.0mg, yield 92.31%).
[0400] MS (ESI, pos.ion) m / z: 502.1 [M+H] + ;
[0401] Step 11: Synthesis of N-(3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0402] To the reaction flask, tert-butyl 5-acetamide-3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (104.0 mg, 0.21 mmol) and N,N-dimethylformamide (3.0 mL) were added. The reaction system was heated to 130°C and stirred for 2.0 h. The mixture was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to afford the product as a yellow solid (56.0 mg, 67.28% yield).
[0403] MS(ESI,pos.ion)m / z:402.21[M+H] + ;
[0404] 1 H NMR (400MHz, CDCl3) δ8.92(s,1H),8.26(s,2H),7.45(s,1H),4.29(t,J=4.0Hz,2H),3.41(s,3H),3.28(t,J=4.0Hz,2H),2.55(s,3H),2.10(s,3H).
[0405] Step 12: Synthesis of N-(1-methyl-3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0406] N-(3-(4-methyl-7-(methylsulfonyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (50.0 mg, 0.12 mmol), cesium carbonate (46.9 mg, 0.14 mmol) and N,N-dimethylformamide (3.0 mL) were added to the reaction flask. Under stirring at room temperature, iodomethane (18.7 mg, 0.13 mmol) was added dropwise. The mixture was stirred at room temperature for 2.0 h and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a yellow solid product (48.0 mg, yield 92.76%).
[0407] MS (ESI, pos.ion) m / z: 416.6 [M+H] + ;
[0408] 1 H NMR(400MHz,DMSO-d6)δ10.25(s,1H),8.95(s,1H),8.63(s,1H),8.48(s,1H),7.21(s,1H),4.3 2(t,J=4.0Hz,2H),3.96(s,3H),3.41(s,3H),3.25(t,J=4.0Hz,2H),2.56(s,3H),2.07(s,3H).
[0409] Example 4: N-(1-methyl-3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0410] Step 1: Synthesis of 1-((tert-butyldimethylsilyl)oxy)propan-2-ol
[0411] To the reaction flask were added propane-1,2-diol (1.50 g, 19.71 mmol), dichloromethane (60 mL), and 1H-imidazole (1.41 g, 20.70 mmol) in sequence. After nitrogen replacement, the mixture was cooled to 0°C, and tert-butyldimethylsilyl chloride (3.12 g, 20.70 mmol) dissolved in dichloromethane (20 mL) was added dropwise. After the addition was complete, the mixture was kept warm and stirred for 2.0 h. Water (50 mL) was added to the above mixture, and the resulting mixture was separated. The aqueous phase was extracted with dichloromethane (30 mL). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give a colorless transparent oily liquid (3.00 g, yield 79.94%).
[0412] MS (ESI, pos.ion) m / z: 191.4 [M+H] + .
[0413] 1 H NMR (400MHz, CDCl3) δ3.87–3.77(m,1H),3.59(dd,J=9.9,3.4Hz,1H),3.35(dd,J=9.8 ,7.8Hz,1H),2.45(d,J=2.8Hz,1H),1.12(d,J=6.3Hz,3H),0.91(s,9H),0.07(s,6H).
[0414] Step 2: Synthesis of 2-bromo-6-iodo-3-(methoxymethoxy)pyridine
[0415] To a reaction flask were added 2-bromo-6-iodopyridin-3-ol (4.00 g, 13.34 mmol), dichloromethane (50 mL), and diisopropylethylamine (2.59 g, 20.01 mmol). The mixture was cooled to 0°C and chloromethyl methyl ether (1.43 g, 16.01 mmol) was added dropwise. After completion of the addition, the mixture was slowly warmed to room temperature and stirred overnight. Water (50 mL), methanol (10 mL), and ethyl acetate (50 mL) were added sequentially. The resulting mixture was separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to afford a colorless, transparent oil (2.60 g, 56.68% yield).
[0416] MS (ESI, pos.ion) m / z: 344.1 [M+H] + .
[0417] 1 H NMR (400MHz, CDCl3) δ7.57 (d, J = 8.4Hz, 1H), 7.11 (d, J = 8.4Hz, 1H), 5.25 (s, 2H), 3.50 (s, 3H).
[0418] Step 3: Synthesis of 2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol
[0419] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridine (2.60 g, 7.56 mmol) and tetrahydrofuran (50 mL) were added sequentially to a reaction flask. After nitrogen replacement, the mixture was cooled to -78°C. Lithium diisopropylamide (4.5 mL, 2.00 mol / L, 9.0 mmol) was then added dropwise to the mixture. After complete addition, the mixture was stirred at this temperature for 1.0 h. Trimethyl borate (1.18 g, 11.34 mmol) was added dropwise to the mixture. After complete addition, the mixture was stirred at this temperature for 2.0 h. The mixture was warmed to -60°C and hydrogen peroxide (1.71 g, 15.12 mmol, 30 wt%) was added dropwise. After complete addition, the mixture was stirred at this temperature for 30 min. The mixture was transferred to 0°C and stirred for 2.0 h. The above mixture was transferred to an ice-salt bath, and a saturated aqueous sodium thiosulfate solution (30 mL) was added thereto. The pH of the mixture was adjusted to 3-4 with hydrochloric acid (1 mol / L). After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (40 mL). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 3 / 1) to give a light yellow solid product (1.50 g, yield 55.13%).
[0420] MS (ESI, pos.ion) m / z: 359.1 [M+H] + .
[0421] 1 H NMR (400MHz, CDCl3) δ8.51(s,1H),7.30(s,1H),5.08(s,2H),3.69(s,3H).
[0422] Step 4: Synthesis of 2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)propan-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine
[0423] To the reaction flask were added 2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (1.00 g, 2.78 mmol), 1-((tert-butyldimethylsilyl)oxy)propan-2-ol (0.58 g, 3.06 mmol), triphenylphosphine (0.87 g, 3.34 mmol), and tetrahydrofuran (15.0 mL) in sequence. Diethyl azodicarboxylate (0.63 g, 3.61 mmol) was added dropwise at room temperature under open conditions. After the addition was complete, the mixture was stirred at room temperature for 30 min. The mixture was concentrated to dryness, and water (30 mL) and ethyl acetate (30 mL) were added thereto in sequence. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to give a light yellow oil product (1.35 g, yield 91.29%).
[0424] MS (ESI, pos.ion) m / z: 532.1 [M+H] + ;
[0425] 1 H NMR (400MHz, CDCl3) δ7.28 (s, 1H), 5.16 (q, J = 5.7Hz, 2H), 4.59–4.47 (m, 1H), 3.76–3. 68(m,2H),3.62(s,3H),1.33(d,J=6.3Hz,3H),0.87(s,9H),0.06(s,3H),0.03(s,3H).
[0426] Step 5: Synthesis of 2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol
[0427] To the reaction flask were added 2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)propan-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine (1.35 g, 2.54 mmol), tetrahydrofuran (7.5 mL), and hydrochloric acid (3.0 mL, 4 mol / L, 12 mmol), and the mixture was stirred at room temperature for 2.0 h. Saturated sodium carbonate solid was added to the mixture to adjust the pH to 3-4. The resulting mixture was diluted with ethyl acetate (30 mL). After separation, the aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 2 / 1) to obtain the product as a white solid (0.85 g, yield 89.62%).
[0428] MS (ESI, pos.ion) m / z: 374.1 [M+H] + ;
[0429] 1 H NMR (400MHz, CDCl3) δ7.17 (s, 1H), 4.53–4.43 (m, 1H), 3.84 (qd, J = 11.9, 4.9Hz, 2H), 1.37 (d, J = 6.3Hz, 3H).
[0430] Step 6: Synthesis of 5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0431] To a reaction flask were added 2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol (777.8 mg, 2.08 mmol), triphenylphosphine (0.65 g, 2.50 mmol), and tetrahydrofuran (30 mL). The mixture was cooled to 0°C, and diethyl azodicarboxylate (0.45 g, 2.6 mmol) was added dropwise. After complete addition, the mixture was slowly warmed to room temperature and stirred for 1.0 h. The solvent was evaporated from the mixture, and water (30 mL) and ethyl acetate (30 mL) were added to the residue. The resulting mixture was separated, and the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to obtain the product (645 mg, 87.19% yield) as a light yellow, opaque oil.
[0432] MS (ESI, pos.ion) m / z: 356.1 [M+H] + ;
[0433] 1 H NMR (400MHz, CDCl3) δ7.26 (s, 1H), 4.41–4.32 (m, 2H), 3.94–3.87 (m, 1H), 1.40 (d, J = 6.5Hz, 3H).
[0434] Step 7: Synthesis of 5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0435] To a reaction flask, 5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (635.0 mg, 1.78 mmol), tris(dibenzylideneacetone)dipalladium (81.0 mg, 0.09 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.10 g, 0.18 mmol), dioxane (2.0 mL), and sodium thiomethoxide (0.12 g, 1.78 mmol) were added sequentially. After nitrogen substitution, the mixture was stirred at 75°C for 3.0 h. The mixture was cooled to room temperature. Water (30 mL) and ethyl acetate (30 mL) were added sequentially. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to give a colorless transparent oil product (240 mg, yield 48.72%).
[0436] MS (ESI, pos.ion) m / z: 276.1 [M+H] + ;
[0437] 1 H NMR (400MHz, CDCl3) δ6.65 (s, 1H), 4.40–4.31 (m, 2H), 3.93–3.84 (m, 1H), 2.51 (s, 3H), 1.39 (d, J = 6.4Hz, 3H).
[0438] Step 8: Synthesis of N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0439] To the reaction flask were added 5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (240.0 mg, 0.87 mmol), tert-butyl 5-acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (418.9 mg, 1.04 mmol), potassium carbonate (0.36 g, 2.61 mmol), [1,1'-[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (36.0 mg, 0.04 mmol), dioxane (6.0 mL), and water (2.0 mL) in sequence. After nitrogen substitution, the mixture was heated to 100°C and stirred overnight. To the above mixture were added water (30 mL) and a mixed solvent (30 mL, dichloromethane / methanol (v / v) = 10 / 1). After the resulting mixture was separated, the aqueous phase was extracted with a mixed solvent (30 mL, dichloromethane / methanol (v / v) = 10 / 1). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a yellow solid product (150 mg, yield 46.59%).
[0440] MS (ESI, pos.ion) m / z: 371.2 [M+H] + .
[0441] Step 9: Synthesis of N-(1-methyl-3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0442] To the reaction flask were added N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (150.0 mg, 0.40 mmol), N,N-dimethylformamide (3.0 mL), cesium carbonate (0.26 g, 0.80 mmol), and iodomethane (68.0 mg, 0.48 mmol) in sequence, and the mixture was stirred at room temperature for 2.0 h. To the above mixture were added water (30 mL) and ethyl acetate (30 mL) in sequence. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a light yellow solid product (118 mg, yield 75.80%).
[0443] MS (ESI, pos.ion) m / z: 385.2 [M+H] + ;
[0444] 1 H NMR(400MHz, CDCl3)δ9.17(s,1H),8.40(s,1H),8.00(s,1H),7.98(s,1H),6.62(s,1H),4.46– 4.37(m,2H),3.99–3.92(m,1H),3.91(s,3H),2.75(s,3H),2.21(s,3H),1.42(d,J=6.4Hz,3H).
[0445] Step 10: Synthesis of N-(1-methyl-3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0446] To the reaction flask, add N-(1-methyl-3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (118.0 mg, 0.31 mmol), dichloromethane (5.0 mL), and methanol (1.0 mL) in sequence until the mixture becomes clear. Cool the mixture to 0°C and add potassium monoperoxysulfate (0.38 g, 0.62 mmol) dissolved in water (3.0 mL) dropwise. After the addition is complete, stir the mixture for 2 hours. Saturated aqueous sodium bicarbonate solution was added to the above mixture to adjust the pH to 8-9. The resulting mixture was extracted with a mixed solvent (dichloromethane:methanol (v / v) = 10:1, 20 mL × 2). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a white solid product (70 mg, 54.76%).
[0447] MS (ESI, pos.ion) m / z: 417.2 [M+H] + ;
[0448] 1H NMR(400MHz, CDCl3)δ9.21(s,1H),8.36(s,1H),8.07(s,1H),8.04(s,1H),7.42(s,1H),4.49(d,J=11.4Hz,1H), 4.44–4.36(m,1H),3.98(dd,J=11.2,8.0Hz,1H),3.90(s,3H),3.55(s,3H),2.22(s,3H),1.41(d,J=6.4Hz,3H).
[0449] Example 5: N-(1-methyl-3-(3-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0450] Step 1: Synthesis of 1-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)propan-2-one
[0451] To the reaction flask, 2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (380.0 mg, 1.06 mmol), tetrahydrofuran (6.0 mL), triphenylphosphine (0.32 g, 1.22 mmol), and hydroxyacetone (94.0 mg, 1.27 mmol) were added sequentially. The mixture was cooled to 0°C. Diethyl azodicarboxylate (0.22 g, 1.27 mmol) was added dropwise to the above mixture. After the addition was complete, the mixture was slowly warmed to room temperature and stirred overnight. After the above mixture was cooled to room temperature, diethyl azodicarboxylate (36.0 mg) was added. After the addition was complete, the mixture was slowly warmed to room temperature and stirred for 3.0 h. To the above mixture were added water (30 mL) and ethyl acetate (30 mL) in sequence. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give the product as a yellow oil (280 mg, yield 63.75%).
[0452] MS (ESI, pos.ion) m / z: 475.9 [M+H] + .
[0453] 1 H NMR (400MHz, CDCl3) δ6.99(s,1H),5.25(s,2H),4.67(s,2H),3.64(s,3H),2.28(s,3H).
[0454] Step 2: Synthesis of 1-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)propan-2-ol
[0455] To a reaction flask, 1-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)propan-2-one (330.0 mg, 0.79 mmol) and ethanol (5.0 mL) were added sequentially. The mixture was cooled to 0°C, and sodium borohydride (31.0 mg, 0.87 mmol) was added. After complete addition, the mixture was stirred for 1.0 h. Water (30 mL) and ethyl acetate (30 mL) were added sequentially to the above mixture. The resulting mixture was separated, and the aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were washed with saturated brine (60 mL), and concentrated to yield the product as a colorless, transparent oil (331 mg, 99.97% yield).
[0456] MS (ESI, pos.ion) m / z: 418.0 [M+H] + .
[0457] Step 3: Synthesis of 2-bromo-4-(2-hydroxypropoxy)-6-iodopyridin-3-ol
[0458] To a reaction flask, 1-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)propan-2-ol (331.0 mg, 0.79 mmol) and ethyl acetate (5.0 mL) were added sequentially, and the mixture was placed in an ice-salt bath. Hydrochloric acid (2.0 mL, 4 mmol / L, 8 mmol) was added dropwise to the mixture. After complete addition, the mixture was transferred to room temperature and stirred for 1.0 h. TLC indicated that the system was primarily composed of the starting material. Concentrated hydrochloric acid (1.0 mL, 37 mass%) was added dropwise to the mixture. After complete addition, the mixture was stirred at room temperature for 1.0 h. TLC indicated that the starting material was substantially reacted. To the above mixture were added water (30 mL) and ethyl acetate (30 mL) in sequence. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 3 / 1) to give a white solid product (224 mg, yield 75.65%).
[0459] MS (ESI, pos.ion) m / z: 373.9 [M+H] + .
[0460] Step 4: Synthesis of 5-bromo-7-iodo-3-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0461] 2-Bromo-4-(2-hydroxypropoxy)-6-iodopyridin-3-ol (224.0 mg, 0.60 mmol), triphenylphosphine (181.0 mg, 0.69 mmol), and tetrahydrofuran (10 mL) were added sequentially to the reaction flask. Diethyl azodicarboxylate (130.6 mg, 0.75 mmol) was slowly added dropwise to the mixture. After complete addition, the mixture was stirred at room temperature for 30 min. Water (30 mL) and ethyl acetate (30 mL) were added sequentially to the mixture. The resulting mixture was separated, and the aqueous phase was extracted with ethyl acetate (30 mL). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to obtain the product as a white solid (130 mg, yield 60.97%).
[0462] MS (ESI, pos.ion) m / z: 355.9 [M+H] + .
[0463] Step 5: Synthesis of 5-bromo-3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0464] To a reaction flask, 5-bromo-7-iodo-3-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (130.0 mg, 0.37 mmol), tris(dibenzylideneacetone)dipalladium (17.0 mg, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (21.0 mg, 0.04 mmol), dioxane (5.0 mL), and sodium thiomethoxide (27.0 mg, 0.39 mmol) were added sequentially. After nitrogen substitution, the mixture was stirred at 75°C for 3.0 h. The mixture was then cooled to room temperature. To the above mixture were added water (30 mL) and ethyl acetate (30 mL) in sequence. After the resulting mixture was separated, the aqueous phase was extracted with ethyl acetate (30 mL). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to give a white solid product (40 mg, yield 39.17%).
[0465] MS (ESI, pos.ion) m / z: 276.2 [M+H] + .
[0466] Step 6: Synthesis of N-(3-(3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0467] To the reaction flask were added 5-bromo-3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (39.5 mg, 0.14 mmol), tert-butyl 5-acetamide-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (73.0 mg, 0.18 mmol), 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride dichloromethane complex (5.7 mg, 0.01 mmol), potassium carbonate (58.0 mg, 0.42 mmol), dioxane (3.0 mL) and water (1.0 mL) in sequence. The mixture was replaced with nitrogen and heated to 100°C and stirred overnight. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give a gray solid product (40 mg, yield 75.49%).
[0468] MS (ESI, pos.ion) m / z: 371.5 [M+H] + .
[0469] Step 7: Synthesis of N-(1-methyl-3-(3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0470] To the reaction flask were added N-(3-(3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (40.0 mg, 0.11 mmol), N,N-dimethylformamide (2.0 mL), cesium carbonate (72.0 mg, 0.22 mmol) and iodomethane (23.0 mg, 0.17 mmol) in sequence, and the mixture was stirred at room temperature for 2.0 h. To the above mixture were added water (10 mL) and a mixed solvent (10 mL, dichloromethane / methanol (v / v) = 10 / 1). After the resulting mixture was separated, the aqueous phase was extracted with a mixed solvent (dichloromethane / methanol (v / v) = 10 / 1, 10 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a gray solid product (38.6 mg, yield 92.98%).
[0471] MS (ESI, pos.ion) m / z: 385.2 [M+H] + .
[0472] Step 8: Synthesis of N-(1-methyl-3-(3-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0473] To a reaction flask, add N-(1-methyl-3-(3-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (38.6 mg, 0.10 mmol), dichloromethane (3.0 mL), and methanol (0.5 mL) in sequence. The mixture is cooled to 0°C, and potassium peroxymonosulfonate (0.12 g, 0.20 mmol) dissolved in water (0.5 mL) is added dropwise. After the addition is complete, the mixture is stirred at this temperature for 2.0 h. Potassium peroxymonosulfonate (40.0 mg) is added to the above mixture, and the mixture is stirred at this temperature for another 2.0 h. Saturated aqueous sodium bicarbonate solution was added to the above mixture to adjust the pH to 9-10. The resulting mixture was extracted with a mixed solvent (dichloromethane / methanol (v / v) = 10 / 1, 20 mL × 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give a white solid product (15 mg, yield 35.87%).
[0474] MS (ESI, pos.ion) m / z: 417.6 [M+H] + ;
[0475] 1 H NMR(400MHz,DMSO-d6)δ10.30(s,1H),9.18(s,1H),8.65(s,1H),8.38(s,1H),7.32(s,1H),4.63 –4.49(m,2H),4.14–4.04(m,1H),3.98(s,3H),3.53(s,3H),2.11(s,3H),1.50(d,J=5.2Hz,3H).
[0476] Example 6: N-(1-methyl-3-(8-(methylsulfonyl)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0477] Step 1: Synthesis of 6-bromo-8-iodo-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridine
[0478] 2-Bromo-6-iodopyridine-3,4-diol (25.0 mg, 0.079 mmol), potassium carbonate (55.0 mg, 0.40 mmol), 1,3-dibromopropane (24.0 mg, 0.12 mmol) and solvent N,N-dimethylformamide (3.0 mL) were added to the reaction flask, and the reaction system was heated to 100°C and stirred for about 2.0 h. The reaction was evaporated to dryness under reduced pressure, and the resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a yellow solid product (12.0 mg, yield 42.60%).
[0479] MS (ESI, pos.ion) m / z: 355.9 [M+H] + ;
[0480] 1 H NMR (400MHz, CDCl3) δ7.23 (s, 1H), 4.40 (dt, J = 12.3, 5.9Hz, 4H), 2.32 (p, J = 6.0Hz, 2H).
[0481] Step 2: Synthesis of 6-bromo-8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridine
[0482] 6-Bromo-8-iodo-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridine (0.75 g, 2.11 mmol), sodium thiomethoxide (0.16 g, 2.22 mmol), Pd2dba3 (97.0 mg, 0.11 mmol), XantPhos (0.12 g, 0.21 mmol) and 1,4-dioxane (20 mL) were added to the reaction flask. After nitrogen ventilation, the mixture was stirred at 85°C overnight and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a crude yellow solid product (0.31 g, yield 53.28%).
[0483] MS (ESI, pos.ion) m / z: 276.0 [M+H] + ;
[0484] 1 H NMR (400MHz, CDCl3) δ6.71 (s, 1H), 4.40–4.35 (m, 2H), 4.32 (t, J = 6.0Hz, 2H), 2.53 (s, 3H), 2.29 (dt, J = 11.6, 5.9Hz, 2H).
[0485] Step 3: Synthesis of N-(3-(8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0486] Add 6-bromo-8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepane[2,3-c]pyridine (310.0 mg, 1.13 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (490.0 mg, 1.23 mmol), potassium carbonate (460.0 mg, 3.36 mmol) to the reaction flask. l), PdCl2dppf-DCM (41.0 mg, 0.056 mmol), then under nitrogen protection, 1,4-dioxane (15.0 mL) and water (3.0 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C, the reaction was stirred overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a crude yellow solid product (170.0 mg, yield 40.88%).
[0487] MS (ESI, pos.ion) m / z: 371.1 [M+H] + .
[0488] Step 4: Synthesis of N-(1-methyl-3-(8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0489] To the reaction flask were added N-(3-(8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (260.0 mg, 0.70 mmol), cesium carbonate (270.0 mg, 0.84 mmol) and N,N-dimethylformamide (15.0 mL). Under stirring at room temperature, iodomethane (110.1 mg, 0.77 mmol) was added dropwise. The reaction was stirred at room temperature for 2.5 h, and the mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a crude yellow solid product (170.0 mg, yield 63.00%).
[0490] MS (ESI, pos.ion) m / z: 385.1 [M+H] + .
[0491] Step 5: Synthesis of N-(1-methyl-3-(8-(methylsulfonyl)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0492] N-(1-methyl-3-(8-(methylthio)-3,4-dihydro-2H-[1,4]dioxepano[2,3-c]pyridin-6-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (170.0 mg, 0.44 mmol), methanol (2.0 mL), tetrahydrofuran (10 mL) and water (2 mL) were added to the reaction flask. Oxone (540.1 mL) was added under stirring at room temperature. mg, 0.88 mmol), and the reaction was continued with stirring at room temperature for about 1.5 h. A saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8. Water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with dichloromethane (40 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a brown solid product (87.0 mg, yield 47.24%).
[0493] MS (ESI, pos.ion) m / z: 417.1 [M+H] + ;
[0494] 1 H NMR(400MHz,DMSO-d6)δ10.18(s,1H),9.07(s,1H),8.62(s,1H),8.41(s,1H),7.30(s,1 H),4.48(d,J=5.7Hz,2H),4.42(t,J=5.6Hz,4H),3.74(s,3H),3.47(s,3H),2.09(s,3H).
[0495] Example 7 (R)-N-(3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0496] Step 1: Synthesis of (S)-1-((tert-butyldimethylsilyl)oxy)propan-2-ol
[0497] To the reaction flask were added (S)-propane-1,2-diol (5.0 g, 65.71 mmol), imidazole (5.37 g, 78.85 mmol) and dichloromethane (100 mL) in sequence. The reaction system was stirred at 0°C, and then a solution of tert-butyldimethylsilyl chloride (11.88 g, 78.85 mmol) in dichloromethane (50 mL) was added dropwise. After the addition was complete, the mixture was stirred at this temperature for 2.0 h. Water (100 mL) was added to the system, and the layers were separated. The aqueous phase was extracted with dichloromethane (50 mL × 2). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 25 / 1) to give the product as a light yellow oily liquid (11.35 g, yield 90.74%).
[0498] MS (ESI, pos.ion) m / z: 191.3 [M+H] + ;
[0499] 1 H NMR (400MHz, CDCl3) δ3.87–3.75(m,1H),3.58(dd,J=9.9,3.4Hz,1H),3.34(dd,J=9.7,7.9Hz,1H),1.11(d,J=6.3Hz,3H),0.90(s,9H),0.07(s,6H).
[0500] Step 2: Synthesis of (R)-2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)prop-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine
[0501] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (5.0 g, 13.89 mmol), (S)-1-((tert-butyldimethylsilyl)oxy)propan-2-ol (2.91 g, 15.28 mmol), triphenylphosphine (4.37 g, 16.67 mmol) and tetrahydrofuran (100 mL) were added to the reaction flask, and then diethyl azodicarboxylate (3.14 g, 18.06 mmol) was added dropwise. After the addition was completed, the reaction was stirred at room temperature for 3.0 hours. The system was concentrated under reduced pressure, and water (100 mL) and ethyl acetate (100 mL) were added. The liquids were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 50 / 1) to give a light yellow oily liquid product (7.09 g, yield 95.89%).
[0502] MS (ESI, pos.ion) m / z: 532.1 [M+H]+ ;
[0503] 1 H NMR(400MHz, CDCl3)δ7.27(s,1H),5.15(q,J=5.7Hz,2H),4.60–4.48(m,1H),3.78–3 .67(m,2H),3.62(s,3H),1.33(d,J=6.3Hz,3H),0.86(s,9H),0.04(d,J=10.6Hz,6H).
[0504] Step 3: Synthesis of (R)-2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol
[0505] To the reaction flask, (R)-2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)prop-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine (7.09 g, 13.32 mmol) and tetrahydrofuran (100 mL) were added, followed by dilute hydrochloric acid (66.60 mL, 266.40 mmol, 4 M). After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, the layers were separated, and the aqueous phase was extracted with ethyl acetate (60 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give a light brown solid product (4.92 g, yield 98.77%).
[0506] MS (ESI, pos.ion) m / z: 374.0 [M+H] + ;
[0507] 1 H NMR (400MHz, CDCl3) δ7.12(s,1H),4.51(s,1H),3.90(s,1H),3.83(s,1H),1.36(s,3H).
[0508] Step 4: Synthesis of (R)-5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0509] To a reaction flask were added (R)-2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol (4.92 g, 13.16 mmol), triphenylphosphine (4.14 g, 15.79 mmol) and tetrahydrofuran (150 mL). The reaction system was stirred at 0°C, and then diethyl azodicarboxylate (3.04 g, 17.11 mmol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 3.0 h. The system was then concentrated under reduced pressure, and water (100 mL) and ethyl acetate (100 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 25 / 1) to give the product as a light yellow oily liquid (4.08 g, yield 87.12%).
[0510] MS (ESI, pos.ion) m / z: 355.9 [M+H] + ;
[0511] 1 H NMR (400MHz, CDCl3) δ7.16 (s, 1H), 4.42–4.31 (m, 2H), 3.90 (dd, J = 11.6, 7.9Hz, 1H), 1.39 (d, J = 6.4Hz, 3H).
[0512] Step 5: Synthesis of (R)-5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0513] To the reaction flask were added (R)-5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (4.08 g, 11.46 mmol), sodium thiomethoxide (1.10 g, 14.90 mmol), Pd2dba3 (0.52 g, 0.57 mmol), XantPhos (0.66 mg, 1.15 mmol) and 1,4-dioxane (150 mL) as solvent. After nitrogen ventilation, the mixture was stirred at 100°C for 6.0 h and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light yellow oily liquid (1.48 g, yield 46.76%).
[0514] MS (ESI, pos.ion) m / z: 276.1 [M+H] + ;
[0515] 1H NMR (400MHz, CDCl3) δ6.64 (s, 1H), 4.38–4.31 (m, 2H), 3.92–3.84 (m, 1H), 2.50 (s, 3H), 1.38 (d, J = 6.4Hz, 3H).
[0516] Step 6: Synthesis of (R)-N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0517] In the reaction flask, (R)-5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (1.48 g, 5.36 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (2.37 g, 5.90 mmol), potassium carbonate (1.48 g, 10.72 mmol) were added. mol), PdCl2dppf-DCM (0.66 g, 0.80 mmol), then under nitrogen protection, 1,4-dioxane (105 mL) and water (42 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred to react overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light yellow solid product (1.65 g, yield 83.11%).
[0518] MS (ESI, pos.ion) m / z: 371.2 [M+H] + ;
[0519] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.10(s,1H),9.06(s,1H),8.52(s,1H),8.27(d,J=2.8Hz,1H),6.64 (s,1H),4.52–4.43(m,2H),3.96(dd,J=11.6,7.8Hz,1H),2.63(s,3H),2.07(s,3H),1.33(d,J=6.3Hz,3H).
[0520] Step 7: Synthesis of (R)-N-(3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0521] (R)-N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (90.0 mg, 0.24 mmol), methanol (10 mL) and tetrahydrofuran (10 mL) were added to the reaction flask. Oxone (0.30 g, 0.48 mmol) was added under stirring at room temperature. ) in water (10 mL), the reaction was continued with stirring at room temperature for 2.0 h, saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8, water (10 mL) was added, the layers were separated, and the aqueous phase was extracted with dichloromethane (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give a light yellow solid product (33.0 mg, yield 33.75%).
[0522] MS (ESI, pos.ion) m / z: 403.1 [M+H] + ;
[0523] 1 H NMR (400MHz, DMSO-d6) δ12.11(s,1H),10.25(s,1H),9.15(s,1H),8.57(s,1H),8.44(d,J=2.6Hz,1H),7.28(s,1H),4.66( dd,J=11.5,1.0Hz,1H),4.61–4.53(m,1H),4.14(dd,J=11.5,7.5Hz,1H),3.51(s,3H),2.10(s,3H),1.39(d,J=6.3Hz,3H).
[0524] Example 8 (S)-N-(3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0525] Step 1: Synthesis of (R)-1-((tert-butyldimethylsilyl)oxy)propan-2-ol
[0526] To the reaction flask were added (R)-propane-1,2-diol (5.0 g, 65.71 mmol), imidazole (5.37 g, 78.85 mmol) and dichloromethane (100 mL) in sequence. A solution of tert-butyldimethylsilyl chloride (11.88 g, 78.85 mmol) in dichloromethane (50 mL) was added dropwise with stirring at 0°C. After the addition was complete, the mixture was stirred for 2.0 h. Water (100 mL) was added to the system, and the layers were separated. The aqueous phase was extracted with dichloromethane (50 mL × 2). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 25 / 1) to give the product as a light yellow oily liquid (11.36 g, yield 90.82%).
[0527] MS (ESI, pos.ion) m / z: 191.2 [M+H] + ;
[0528] 1 H NMR (400MHz, CDCl3) δ3.86–3.76(m,1H),3.59(dd,J=9.9,3.4Hz,1H),3.34(dd,J=9.8,7.9Hz,1H),1.11(d,J=6.3Hz,3H),0.90(s,9H),0.07(s,6H).
[0529] Step 2: Synthesis of (S)-2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)prop-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine
[0530] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (5.0 g, 13.89 mmol), (R)-1-((tert-butyldimethylsilyl)oxy)propan-2-ol (2.91 g, 15.58 mmol), triphenylphosphine (4.37 g, 16.67 mmol) and tetrahydrofuran (100 mL) were added to the reaction flask, and diethyl azodicarboxylate (3.14 g, 18.06 mmol) was added dropwise with stirring at 0°C. mol), after the addition was completed, the reaction was stirred at room temperature for 3.0 h, and the system was concentrated under reduced pressure. Water (100 mL) and ethyl acetate (100 mL) were added, and the liquids were separated. The aqueous phase was extracted with ethyl acetate (50 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The mother liquor was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 50 / 1) to give a light yellow oily liquid product (6.61 g, yield 89.40%).
[0531] MS (ESI, pos.ion) m / z: 532.1 [M+H]+ ;
[0532] 1 H NMR (400MHz, CDCl3) δ7.27 (s, 1H), 5.15 (q, J = 5.7Hz, 2H), 4.59–4.48 (m, 1H), 3.78–3 .67(m,2H),3.61(s,3H),1.33(d,J=6.3Hz,3H),0.86(s,9H),0.04(d,J=10.6Hz,6H).
[0533] Step 3: Synthesis of (S)-2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol
[0534] To the reaction flask, (S)-2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)prop-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine (6.61 g, 12.42 mmol) and tetrahydrofuran (100 mL) were added, followed by dilute hydrochloric acid (62.10 mL, 248.40 mmol, 4 M). After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, the layers were separated, and the aqueous phase was extracted with ethyl acetate (60 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give a light brown solid product (4.33 g, yield 93.24%).
[0535] MS (ESI, pos.ion) m / z: 374.0 [M+H] + ;
[0536] 1 H NMR (400MHz, CDCl3) δ7.12 (s, 1H), 4.56–4.45 (m, 1H), 3.90 (d, J = 11.0Hz, 1H), 3.81 (dd, J = 11.7, 6.3Hz, 1H), 1.36 (d, J = 6.1Hz, 3H).
[0537] Step 4: Synthesis of (S)-5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0538] To a reaction flask were added (S)-2-bromo-4-((1-hydroxypropan-2-yl)oxy)-6-iodopyridin-3-ol (4.33 g, 11.58 mmol), triphenylphosphine (3.64 g, 13.90 mmol) and tetrahydrofuran (150 mL). The reaction system was stirred at 0°C and diethyl azodicarboxylate (2.68 g, 15.05 mmol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 3.0 h. The system was then concentrated under reduced pressure, and water (100 mL) and ethyl acetate (100 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 25 / 1) to give the product as a light yellow oily liquid (3.66 g, yield 88.80%).
[0539] MS (ESI, pos.ion) m / z: 355.9 [M+H] + ;
[0540] 1 H NMR (400MHz, CDCl3) δ7.16 (s, 1H), 4.42–4.31 (m, 2H), 3.90 (dd, J = 11.5, 7.8Hz, 1H), 1.40 (d, J = 6.4Hz, 3H).
[0541] Step 5: Synthesis of (S)-5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0542] To the reaction flask were added (S)-5-bromo-7-iodo-2-methyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (3.66 g, 10.28 mmol), sodium thiomethoxide (0.99 g, 13.36 mmol), Pd2dba3 (0.47 g, 0.51 mmol), XantPhos (0.59 mg, 1.03 mmol) and solvent 1,4-dioxane (150 mL). After nitrogen ventilation, the mixture was stirred at 100°C for 6.0 h and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light yellow oily liquid (0.97 g, yield 34.16%).
[0543] MS (ESI, pos.ion) m / z: 276.0 [M+H] + ;
[0544] 1H NMR (400MHz, CDCl3) δ6.64 (s, 1H), 4.38–4.31 (m, 2H), 3.92–3.84 (m, 1H), 2.50 (s, 3H), 1.38 (d, J = 6.4Hz, 3H).
[0545] Step 6: Synthesis of (S)-N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0546] In the reaction flask, (S)-5-bromo-2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (0.97 g, 3.51 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (1.55 g, 3.86 mmol), potassium carbonate (0.97 g, 3.02 mmol) were added. l), PdCl2dppf-DCM (0.43 g, 0.53 mmol), then under nitrogen protection, 1,4-dioxane (105 mL) and water (42.0 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C, the reaction was stirred overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light yellow solid product (800.0 mg, yield 61.48%).
[0547] MS (ESI, pos.ion) m / z: 371.2 [M+H] + ;
[0548] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.10(s,1H),9.06(s,1H),8.52(s,1H),8.27(d,J=2.7Hz,1H) ,6.64(s,1H),4.55–4.40(m,2H),4.03–3.91(m,1H),2.64(s,3H),2.08(s,3H),1.33(d,J=6.3Hz,3H).
[0549] Step 7: Synthesis of (S)-N-(3-(2-methyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0550] In the reaction flask, (S)-N-(3-(2-methyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (90.0 mg, 0.24 mmol), methanol (10 mL) and tetrahydrofuran (10 mL) were added. Under stirring at room temperature, Oxone (0.30 g, 0.48 mmol) was added. ) in water (10 mL), the reaction was continued with stirring at room temperature for 2.0 h, saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8, water (10 mL) was added, the layers were separated, and the aqueous phase was extracted with dichloromethane (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give a light yellow solid product (28.7 mg, yield 29.35%).
[0551] MS (ESI, pos.ion) m / z: 403.1 [M+H] + ;
[0552] 1 H NMR (400MHz, DMSO-d6) δ12.12(s,1H),10.25(s,1H),9.15(s,1H),8.57(s,1H),8.44(d,J=2.6Hz,1H),7.28(s,1H),4 .69–4.62(m,1H),4.61–4.53(m,1H),4.13(dd,J=11.5,7.5Hz,1H),3.51(s,3H),2.10(s,3H),1.38(d,J=6.3Hz,3H).
[0553] Example 9 N-(3-(2,3-dimethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0554] Step 1: Synthesis of 3-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)butan-2-one
[0555] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (1.91 g, 5.31 mmol), 3-hydroxybutan-2-one (0.72 g, 7.96 mmol), triphenylphosphine (1.67 g, 6.37 mmol) and tetrahydrofuran (50 mL) were added to the reaction flask, and then diethyl azodicarboxylate (1.20 g, 6.90 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2 h. The system was concentrated under reduced pressure, and water (50 mL) and ethyl acetate (50 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give an off-white solid product (1.4 g, yield 61.35%).
[0556] MS (ESI, pos.ion) m / z: 430.0 [M+H] + ;
[0557] 1 H NMR (400MHz, CDCl3) δ6.94(s,1H),5.22(dd,J=13.2,5.8Hz,2H),4.71(q,J=6.9Hz,1H),3.64(s,3H),2.21(s,3H),1.58(d,J=6.9Hz,3H).
[0558] Step 2: Synthesis of 3-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)butan-2-ol
[0559] 3-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)butan-2-one (1.4 g, 3.26 mmol) and anhydrous ethanol (60 mL) were added to the reaction flask, the mixture was cooled to 0°C, sodium borohydride (0.18 g, 4.89 mmol) was added, and after the addition was complete, the system was moved to room temperature and stirred for 2.0 h. The system was concentrated under reduced pressure, water (50 mL) and ethyl acetate (50 mL) were added, the liquids were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give a light yellow oily liquid product (1.30 g, yield 92.42%).
[0560] MS (ESI, pos.ion) m / z: 432.0 [M+H] + ;
[0561] 1H NMR(400MHz, CDCl3) δ7.16(s,1H),5.30(dd,J=6.0,2.4Hz,1H),5.05(dd,J=18.3,6.0Hz,1H),4 .22–4.07(m,1H),3.90–3.80(m,1H),3.60(s,3H),1.33(d,J=6.2Hz,3H),1.23(d,J=6.4Hz,3H).
[0562] Step 3: Synthesis of 2-bromo-4-((3-hydroxybutan-2-yl)oxy)-6-iodopyridin-3-ol
[0563] 3-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)butan-2-ol (1.3 g, 3.01 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then dilute hydrochloric acid (15.05 mL, 60.20 mmol, 4 M) was added. After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, and the layers were separated. The aqueous phase was extracted with ethyl acetate (60 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give an off-white solid product (1.1 g, yield 94.22%).
[0564] MS (ESI, pos.ion) m / z: 388.0 [M+H] + ;
[0565] 1 H NMR (400MHz, CDCl3) δ7.10(s,1H),4.24–4.08(m,1H),4.03–3.94(m,1H),1.38–1.32(m,3H),1.32–1.28(m,3H).
[0566] Step 4: Synthesis of 5-bromo-7-iodo-2,3-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0567] 2-Bromo-4-((3-hydroxybutan-2-yl)oxy)-6-iodopyridin-3-ol (1.03 g, 2.65 mmol), triphenylphosphine (1.39 g, 5.30 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then diethyl azodicarboxylate (0.97 g, 5.57 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 6 h. The system was concentrated under reduced pressure, and water (30 mL) and ethyl acetate (50 mL) were added. The liquids were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light brown oily liquid product (920 mg, yield 93.67%).
[0568] MS (ESI, pos.ion) m / z: 369.9 [M+H] + ;
[0569] 1 H NMR(400MHz, CDCl3)δ7.15(s,1H),4.43–4.33(m,1H),3.99–3.87(m,1H),1.44(d, J=6.1Hz,1H),1.38(d,J=6.1Hz,1H),1.33(d,J=6.5Hz,2H),1.29(d,J=6.6Hz,2H).
[0570] Step 5: Synthesis of 5-bromo-2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0571] 5-Bromo-7-iodo-2,3-dimethyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (650.0 mg, 1.76 mmol), sodium thiomethoxide (140 mg, 1.94 mmol), Pd2dba3 (81.0 mg, 0.088 mmol), XantPhos (100.0 mg, 0.18 mmol) and solvent 1,4-dioxane (30 mL) were added to the reaction flask. After nitrogen ventilation, the mixture was stirred at 100°C for 8 h and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light yellow oily liquid (264.0 mg, yield 51.78%).
[0572] MS (ESI, pos.ion) m / z: 290.1 [M+H] + ;
[0573] 1H NMR (400MHz, CDCl3) δ6.63(s,1H),4.42–4.30(m,2H),2.50(s,3H),1.34–1.27(m,6H).
[0574] Step 6: Synthesis of N-(3-(2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0575] 5-Bromo-2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (290.0 mg, 1.0 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (440.0 mg, 1.1 mmol), potassium carbonate (280.0 mg, 2.0 mmol) were added to the reaction flask. mol), PdCl2dppf-DCM (120.0 mg, 0.15 mmol), then under nitrogen protection, 1,4-dioxane (25 mL) and water (10 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred for 6 hours, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a yellow solid product (278.0 mg, yield 72.36%).
[0576] MS (ESI, pos.ion) m / z: 385.2 [M+H] + ;
[0577] 1 H NMR(400MHz,DMSO-d6)δ11.77(s,1H),10.10(s,1H),9.06(s,1H),8.52(s,1H),8.28(s,1H),6.64(s,1H),4.56–4.4 3(m,1H),4.16–3.99(m,1H),2.64(s,3H),2.08(s,3H),1.38(dd,J=38.9,6.2Hz,3H),1.28(dd,J=23.7,6.4Hz,3H).
[0578] Step 7: Synthesis of N-(3-(2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0579] To the reaction flask were added N-(3-(2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (278.0 mg, 0.72 mmol), cesium carbonate (300.0 mg, 0.94 mmol) and solvent N,N-dimethylformamide (20 mL). Under stirring at room temperature, iodomethane (120.0 mg, 0.86 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h. The mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give a crude yellow solid product (205.0 mg, yield 71.14%).
[0580] MS (ESI, pos.ion) m / z: 399.1 [M+H] + ;
[0581] 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H),9.06(s,1H),8.61(s,1H),8.24(s,1H),6.63(s,1H),4.56–4.43( m,1H),4.16–3.99(m,1H),3.95(s,3H),2.63(s,3H),2.08(s,3H),1.38–1.29(m,3H),1.28–1.18(m,3H).
[0582] Step 8: Synthesis of N-(3-(2,3-dimethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0583] N-(3-(2,3-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (205.0 mg, 0.51 mmol), methanol (16 mL) and tetrahydrofuran (16 mL) were added to the reaction flask, and Oxone (630.0 mg, 1.02 mL) was added under stirring at room temperature. The product was added to a 1% mol (100 mol) water (16 mL) solution, and the reaction was continued with stirring at room temperature for 2.0 h. A saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8. Water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with dichloromethane (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give an off-white solid product (130.0 mg, yield 58.70%).
[0584] MS (ESI, pos.ion) m / z: 431.1 [M+H] + ;
[0585] 1 H NMR (400MHz, DMSO-d6) δ10.30(s,1H),9.17(s,1H),8.65(s,1H),8.37(d,J=18.8Hz,1H),7.28(d,J=3.4H z,1H),4.71–4.59(m,1H),4.27–4.16(m,1H),3.98(s,3H),3.53(s,3H),2.11(s,3H),1.56–1.27(m,6H).
[0586] Example 10 N-(3-(2,2-dimethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0587] Step 1: Synthesis of methyl 2-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)acetate
[0588] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (3.13 g, 8.70 mmol), potassium iodide (1.44 g, 8.70 mmol), potassium carbonate (2.40 g, 17.4 mmol) and N,N-dimethylformamide (80 mL) were added to the reaction flask. Methyl 2-bromoacetate (2.00 g, 13.05 mmol) was added under stirring at room temperature. The reaction system was heated to 50°C and stirred for about 2.0 h. Water (100 mL) and ethyl acetate (100 mL) were added, the layers were separated, and the aqueous phase was extracted with ethyl acetate (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give the product as a yellow oil (2.46 g, yield 65.43%).
[0589] MS (ESI, pos.ion) m / z: 432.0 [M+H] + ;
[0590] 1 H NMR (400MHz, CDCl3) δ7.06(s,1H),5.27(s,2H),4.72(s,2H),3.85(s,3H),3.66(s,3H).
[0591] Step 2: Synthesis of methyl 2-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)-2-methylpropanoate
[0592] Methyl 2-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)acetate (110.0 mg, 0.25 mmol) and anhydrous tetrahydrofuran (3.0 mL) were added to the reaction flask, and the reaction system was stirred at -78 ° C. Lithium bis(trimethylsilyl)amide (0.55 mL, 0.55 mmol) was added dropwise to the reaction system. After the addition was complete, the mixture was stirred at low temperature for 30 minutes, and then iodomethane (106.5 mg, 0.75 mmol) was added dropwise. After the addition was complete, the mixture was stirred at low temperature for about 2 hours. If there was any raw material left, the mixture was heated to -30 ° C and stirred for about 2 hours. Saturated ammonium chloride solution (10 mL) was added to quench the reaction, and the mixture was separated. The aqueous phase was extracted with ethyl acetate (30 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light yellow oil (61.0 mg, yield 52.07%).
[0593] MS (ESI, pos.ion) m / z: 460.0 [M+H] + ;
[0594] 1 H NMR (400MHz, CDCl3) δ6.89(s,1H),5.19(s,2H),3.80(s,3H),3.65(s,3H),1.70(s,6H).
[0595] Step 3: Synthesis of methyl 2-((2-bromo-3-(methoxymethoxy)-6-(methylthio)pyridin-4-yl)oxy)-2-methylpropanoate
[0596] To the reaction flask were added methyl 2-((2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl)oxy)-2-methylpropanoate (60.0 mg, 0.13 mmol), sodium thiomethoxide (11.6 mg, 0.17 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (15.0 mg, 0.03 mmol), tris(dibenzylideneacetone)dipalladium (11.9 mg, 0.01 mmol) and solvent 1,4-dioxane (3.0 mL). The atmosphere was replaced with nitrogen and the reaction system was reacted at 90° C. overnight. The product was concentrated under reduced pressure and the residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give the product as a colorless, transparent oil (31.0 mg, yield 62.51%).
[0597] MS (ESI, pos.ion) m / z: 380.0 [M+H]+ ;
[0598] 1 H NMR (400MHz, CDCl3) δ6.40(s,1H),5.15(s,2H),3.78(s,3H),3.67(s,3H),2.51(s,3H),1.69(s,6H).
[0599] Step 4: Synthesis of 2-((2-bromo-3-(methoxymethoxy)-6-(methylthio)pyridin-4-yl)oxy)-2-methylpropan-1-ol
[0600] Methyl 2-((2-bromo-3-(methoxymethoxy)-6-(methylthio)pyridin-4-yl)oxy)-2-methylpropanoate (37.0 mg, 0.10 mmol) and tetrahydrofuran (3.0 mL) were added to the reaction flask, and the reaction system was stirred at -5 ° C. Lithium aluminum tetrahydride (6.1 mg, 0.16 mmol) was slowly added in batches. After the addition was complete, the temperature was raised to 0 ° C. and stirred for about 1.0 h. Saturated aqueous ammonium chloride (10 mL) and ethyl acetate (30 mL) were slowly added, stirred for 5 minutes, separated, and the aqueous phase was extracted with ethyl acetate (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 3 / 1) to give the product as a light yellow oil (22.0 mg, yield 64.19%).
[0601] MS (ESI, pos.ion) m / z: 352.1 [M+H] + ;
[0602] 1 H NMR (400MHz, CDCl3) δ6.84(s,1H),5.10(s,2H),3.65(s,3H),3.57(s,2H),3.29(s,1H),2.55(s,3H),1.44(s,6H).
[0603] Step 5: Synthesis of 2-bromo-4-((1-hydroxy-2-methylpropan-2-yl)oxy)-6-(methylthio)pyridin-3-ol
[0604] 2-((2-bromo-3-(methoxymethoxy)-6-(methylthio)pyridin-4-yl)oxy)-2-methylpropan-1-ol (121.0 mg, 0.34 mmol) and tetrahydrofuran (3.0 mL) were added to the reaction flask and stirred under ice bath. Diluted hydrochloric acid (4.0 mol / L, 1.68 mL, 6.80 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for about 5.0 h, and ethyl acetate (20 mL) was added to dilute the mixture. The pH was adjusted to 4-6 with saturated sodium bicarbonate solution. The layers were separated, and the aqueous phase was extracted with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 3 / 1) to give the product as a light yellow oil (105.0 mg, yield 99.18%).
[0605] MS (ESI, pos.ion) m / z: 308.0 [M+H] + ;
[0606] 1 H NMR (400MHz, CDCl3) δ6.80(s,1H),3.68(s,2H),2.55(s,3H),1.37(s,6H).
[0607] Step 6: Synthesis of 5-bromo-2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0608] 2-Bromo-4-((1-hydroxy-2-methylpropane-2-yl)oxy)-6-(methylthio)pyridin-3-ol (105.0 mg, 0.34 mmol), triphenylphosphine (178.4 mg, 0.68 mmol) and tetrahydrofuran (5.0 mL) were added to the reaction flask and stirred under ice bath. Diethyl azodicarboxylate (124.3 mg, 0.71 mmol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for about 10 h. Water (10 mL) and ethyl acetate (30 mL) were added, the liquids were separated, the aqueous phase was extracted with ethyl acetate (20 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give the product as a yellow oil (27.0 mg, yield 27.31%).
[0609] MS (ESI, pos.ion) m / z: 290.0 [M+H] + ;
[0610] 1 H NMR (400MHz, CDCl3) δ6.64(s,1H),4.00(s,2H),2.52(s,3H),1.39(s,6H).
[0611] Step 7: Synthesis of N-(3-(2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0612] Add 5-bromo-2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (27.0 mg, 0.09 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (37.0 mg, 0.09 mmol), potassium carbonate (26.0 mg, 0.19 mmol) to the reaction flask. ), PdCl2(dppf)-DCM (7.6 mg, 0.009 mmol), then under nitrogen protection, 1,4-dioxane (4.0 mL) and water (2.0 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred for about 5.0 hours, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give a yellow-brown solid product (35.0 mg, yield 97.84%).
[0613] MS (ESI, pos.ion) m / z: 385.1 [M+H] + ;
[0614] 1 H NMR (400MHz, CDCl3) δ9.05(s,1H),8.16(s,1H),7.37(s,1H),6.56(s,1H),3.99(s,2H),2.66(s,3H),2.19(s,3H),1.37(s,6H).
[0615] Step 8: Synthesis of N-(3-(2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0616] To the reaction flask were added N-(3-(2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (35.0 mg, 0.09 mmol), cesium carbonate (36.0 mg, 0.11 mmol) and solvent N,N-dimethylformamide (2.0 mL). Under stirring at room temperature, iodomethane (15.2 mg, 0.11 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h, and the mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give a yellow solid product (33.0 mg, yield 90.97%).
[0617] MS (ESI, pos.ion) m / z: 399.2 [M+H] + ;
[0618] 1 H NMR (400MHz, CDCl3) δ9.17(s,1H),8.42(s,1H),8.03(s,2H),6.62(s,1H),4.06(s,2H),3.94(s,3H),2.77(s,3H),2.23(s,3H),1.43(s,6H).
[0619] Step 9: Synthesis of N-(3-(2,2-dimethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0620] N-(3-(2,2-dimethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (92.0 mg, 0.23 mmol), methanol (5.0 mL), tetrahydrofuran (5.0 mL) and water (3.0 mL) were added to the reaction flask, and Oxone (282.8 mg, 0.23 mmol) was added under stirring at room temperature. mg, 0.46 mmol), and the reaction was continued at room temperature for about 1.0 h. Saturated sodium bicarbonate solution was slowly added to adjust the pH to 7-8. Water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with dichloromethane (50 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 30 / 1) to give an off-white solid product (57.0 mg, yield 57.35%).
[0621] MS (ESI, pos.ion) m / z: 431.2 [M+H] + ;
[0622] 1 H NMR(400MHz,DMSO-d6)δ10.30(s,1H),9.18(s,1H),8.67(s,1H),8.45(s,1H), 7.25(s,1H),4.28(s,2H),3.99(s,3H),3.53(s,3H),2.11(s,3H),1.41(s,6H).
[0623] Example 11 N-(3-(2-ethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0624] Step 1: Synthesis of 2-((tert-butyldimethylsilyl)oxy)ethan-1-ol
[0625] To the reaction flask at 0°C, ethane-1,2-diol (5.0 g, 80.55 mmol), imidazole (8.23 g, 120.82 mmol) and DCM (100 mL) were added in sequence, and then a solution of tert-butyldimethylsilyl chloride (12.14 g, 80.55 mmol) in DCM (50 mL) was added dropwise. After the addition was complete, the mixture was stirred at room temperature and reacted overnight. The system was washed twice with water (50 mL × 2), and the organic phase was washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 50 / 1) to give a light yellow oily liquid product (4.0 g, yield 28.16%).
[0626] MS (ESI, pos.ion) m / z: 177.3 [M+H] + ;
[0627] 1 H NMR (400MHz, CDCl3) δ3.72–3.68(m,2H),3.67–3.60(m,2H),2.13(s,1H),0.90(s,9H),0.08(s,6H).
[0628] Step 2: Synthesis of 2-((tert-butyldimethylsilyl)oxy)acetaldehyde
[0629] 2-((tert-Butyldimethylsilyl)oxy)ethane-1-ol (7.43 g, 42.14 mmol) and tetrahydrofuran (100 mL) were added to the reaction flask, and Dess-Martin periodinane (19.66 g, 46.35 mmol) was added in batches. After the addition was complete, the reaction was stirred at room temperature for 4 h. Saturated sodium bicarbonate solution (50 mL) and saturated sodium thiosulfate aqueous solution (50 mL) were added and stirred at room temperature for 20 min. Ethyl acetate (100 mL × 2) was added for extraction. The organic phase was washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give a light yellow oily liquid product (4.0 g, yield 54.46%).
[0630] 1 H NMR (400MHz, CDCl3) δ9.69 (s, 1H), 4.20 (s, 2H), 0.92 (s, 9H), 0.10 (s, 6H).
[0631] Step 3: Synthesis of 1-((tert-butyldimethylsilyl)oxy)butan-2-ol
[0632] To the reaction flask at 0°C, 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (1.5 g, 8.61 mmol) and tetrahydrofuran (50 mL) were added sequentially, and then ethylmagnesium bromide (5.74 mL, 17.22 mmol, 3M in THF) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 4.0 h. Saturated ammonium chloride solution (40 mL) was added to the system to quench the reaction, and then extracted with ethyl acetate (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 30 / 1) to give the product as a light yellow oily liquid (1.04 g, yield 59.13%).
[0633] 1 H NMR (400MHz, CDCl3) δ3.63 (dd, J=9.7, 3.3Hz, 1H), 3.59–3.51 (m, 1H), 3.39 (dd, J=9.6, 7.4 Hz,1H),2.43(s,1H),1.50–1.38(m,2H),0.95(t,J=7.5Hz,3H),0.90(s,9H),0.07(s,6H).
[0634] Step 4: Synthesis of 2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)butan-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine
[0635] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (1.60 g, 4.45 mmol), 1-((tert-butyldimethylsilyl)oxy)butan-2-ol (1000.44 mg, 4.90 mmol), triphenylphosphine (2.33 g, 8.9 mmol) and tetrahydrofuran (50 mL) were added to the reaction flask, and then diethyl azodicarboxylate (1.63 g, 9.35 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2 h. The system was concentrated under reduced pressure, and water (60 mL) and ethyl acetate (60 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 30 / 1) to give the product as a light pink oily liquid (2.29 g, yield 94.30%).
[0636] MS (ESI, pos.ion) m / z: 546.0 [M+H] + ;
[0637] 1 H NMR(400MHz, CDCl3)δ7.31(s,1H),5.16(q,J=5.7Hz,2H),4.39–4.31(m,1H),3.80–3.69(m,2H) ,3.62(s,3H),1.79–1.63(m,2H),0.98(t,J=7.5Hz,3H),0.85(s,9H),0.04(s,3H),0.01(s,3H).
[0638] Step 5: Synthesis of 2-bromo-4-((1-hydroxybutan-2-yl)oxy)-6-iodopyridin-3-ol
[0639] 2-Bromo-4-((1-((tert-butyldimethylsilyl)oxy)but-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine (2.18 g, 3.99 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, followed by dilute hydrochloric acid (19.95 mL, 79.80 mmol, 4 M). After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, the layers were separated, and the aqueous phase was extracted with ethyl acetate (60 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give an off-white solid product (1.49 g, yield 96.24%).
[0640] MS (ESI, pos.ion) m / z: 387.9 [M+H] + ;
[0641] 1 H NMR (400MHz, CDCl3) δ7.76(s,1H),7.13(s,1H),4.34–4.24(m,1H),3.96–3.79(m,2H),3.41(s,1H),1.83–1.70(m,2H),0.99(t,J=7.5Hz,3H).
[0642] Step 6: Synthesis of 5-bromo-2-ethyl-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0643] 2-Bromo-4-((1-hydroxybutan-2-yl)oxy)-6-iodopyridin-3-ol (1.49 g, 3.84 mmol), triphenylphosphine (2.01 g, 7.68 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then diethyl azodicarboxylate (1.40 g, 8.06 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2.0 h. The system was concentrated under reduced pressure, and water (30 mL) and ethyl acetate (50 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light pink solid product (1.35 g, yield 95.02%).
[0644] MS (ESI, pos.ion) m / z: 369.9 [M+H] + ;
[0645] 1 H NMR (400MHz, CDCl3) δ7.18 (s, 1H), 4.40 (dd, J = 11.6, 2.2Hz, 1H), 4.18–4.09 (m ,1H),3.96(dd,J=11.6,7.7Hz,1H),1.82–1.61(m,2H),1.07(t,J=7.5Hz,3H).
[0646] Step 7: Synthesis of 5-bromo-2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0647] 5-Bromo-2-ethyl-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (1.35 g, 3.65 mmol), sodium thiomethoxide (320.0 mg, 4.38 mmol), Pd2dba3 (170.0 mg, 0.18 mmol), XantPhos (210.0 mg, 0.36 mmol) and solvent 1,4-dioxane (60 mL) were added to the reaction flask. After nitrogen ventilation, the mixture was stirred at 100°C for overnight and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light yellow oily liquid (476.0 mg, yield 44.96%).
[0648] MS (ESI, pos.ion) m / z: 290.0 [M+H] + ;
[0649] 1 H NMR (400MHz, CDCl3) δ6.66 (s, 1H), 4.36 (dd, J=11.5, 2.2Hz, 1H), 4.16–4.09 (m, 1H), 3.94(dd,J=11.5,7.6Hz,1H),2.50(s,3H),1.80–1.62(m,2H),1.07(t,J=7.5Hz,3H).
[0650] Step 8: Synthesis of N-(3-(2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0651] Add 5-bromo-2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (456.0 mg, 1.57 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (690.0 mg, 1.73 mmol), potassium carbonate (430.0 mg, 3.14 mmol) to the reaction flask. ol), PdCl2dppf-DCM (190.0 mg, 0.14 mmol), then under nitrogen protection, 1,4-dioxane (25 mL) and water (10 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred to react overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light yellow solid product (446.0 mg, yield 73.82%).
[0652] MS (ESI, pos.ion) m / z: 385.1 [M+H] + ;
[0653] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.10(s,1H),9.06(s,1H),8.52(s,1H),8.27(d,J=2.8Hz,1H),6.65(s,1H),4.51(dd,J=11.5,2 .0Hz,1H),4.26(q,J=6.4Hz,1H),4.04(dd,J=11.6,7.4Hz,1H),2.64(s,3H),2.08(s,3H),1.68(p,J=7.3Hz,2H),1.02(t,J=7.5Hz,3H).
[0654] Step 9: Synthesis of N-(3-(2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0655] To a reaction flask were added N-(3-(2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (440.0 mg, 1.14 mmol), cesium carbonate (480.0 mg, 1.48 mmol) and solvent N,N-dimethylformamide (20 mL). Under stirring at room temperature, iodomethane (190.0 mg, 1.37 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h. Water (1.0 mL) was added to the system, and the system was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give the product as a light yellow solid (404.0 mg, yield 88.59%).
[0656] MS (ESI, pos.ion) m / z: 399.1 [M+H] + ;
[0657] 1H NMR (400MHz, DMSO-d6) δ10.16(s,1H),9.08(s,1H),8.61(s,1H),8.24(s,1H),6.64(s,1H),4.49(dd,J=11.5,1.9Hz,1H),4.30– 4.22(m,1H),4.04(dd,J=11.6,7.3Hz,1H),3.93(s,3H),2.64(s,3H),2.08(s,3H),1.68(p,J=7.3Hz,2H),1.02(t,J=7.4Hz,3H).
[0658] Step 10: Synthesis of N-(3-(2-ethyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0659] N-(3-(2-ethyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (360.0 mg, 0.90 mmol), methanol (18 mL) and tetrahydrofuran (18 mL) were added to the reaction flask. Oxone (1.11 g, 1.8 mmol) was added under stirring at room temperature. ) in water (18 mL), and the reaction was continued with stirring at room temperature for 2.0 h. A saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8. Water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with dichloromethane (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give a light yellow solid product (250.0 mg, yield 64.28%).
[0660] MS (ESI, pos.ion) m / z: 431.1 [M+H] + ;
[0661] 1 H NMR (400MHz, DMSO-d6) δ10.29(s,1H),9.18(s,1H),8.65(s,1H),8.41(s,1H),7.29(s,1H),4.64(dd,J=11.5,1.8Hz,1H),4.41– 4.32(m,1H),4.21(dd,J=11.6,7.1Hz,1H),3.97(s,3H),3.52(s,3H),2.10(s,3H),1.72(p,J=7.3Hz,2H),1.04(t,J=7.4Hz,3H).
[0662] Example 12 N-(3-(2-isopropyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0663] Step 1: Synthesis of 1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-ol
[0664] To the reaction flask at 0°C were added 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (836 mg, 4.80 mmol) and tetrahydrofuran (50 mL), followed by dropwise addition of isopropylmagnesium bromide (9.6 mL, 9.6 mmol, 1 M in THF). After the addition was complete, the mixture was stirred at room temperature for 4 h. Saturated ammonium chloride solution (40 mL) was added to the system to quench the reaction, followed by extraction with ethyl acetate (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 30 / 1) to give the product as a light yellow oily liquid (558 mg, yield 53.27%).
[0665] 1 H NMR (400MHz, CDCl3) δ3.68 (dd, J=9.8, 3.3Hz, 1H), 3.46 (dd, J=9.8, 7.9Hz, 1H), 3.33–3.26 (m, 1H), 2. 48(s,1H),1.74–1.61(m,1H),0.97(d,J=6.8Hz,3H),0.90(s,9H),0.88(d,J=6.8Hz,3H),0.07(s,6H).
[0666] Step 2: Synthesis of 2-bromo-4-((1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine
[0667] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (800.0 mg, 2.22 mmol), 1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-ol (530.0 mg, 2.44 mmol), triphenylphosphine (1.16 g, 4.44 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then diethyl azodicarboxylate (0.81 g, 4.66 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2 h. The system was concentrated under reduced pressure, and water (30 mL) and ethyl acetate (30 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (40 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 50 / 1) to give the product as a light pink oily liquid (836 mg, yield 67.13%).
[0668] MS (ESI, pos.ion) m / z: 560.0 [M+H] + ;
[0669] 1 H NMR (400MHz, CDCl3) δ7.35(s,1H),5.16(q,2H),4.24–4.18(m,1H),3.82(dd,J=11.1,3.3Hz,1H),3.73(dd,J=11 .1,6.9Hz,1H),3.63(s,3H),2.08–1.97(m,1H),0.99(t,J=6.8Hz,6H),0.84(s,9H),0.03(s,3H),-0.01(s,3H).
[0670] Step 3: Synthesis of 2-bromo-4-((1-hydroxy-3-methylbutan-2-yl)oxy)-6-iodopyridin-3-ol
[0671] 2-Bromo-4-((1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-yl)oxy)-6-iodo-3-(methoxymethoxy)pyridine (732.2 mg, 1.31 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, followed by dilute hydrochloric acid (6.55 mL, 26.20 mmol, 4 M). After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, the layers were separated, and the aqueous phase was extracted with ethyl acetate (60 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give an off-white solid product (457.0 mg, yield 86.99%).
[0672] MS (ESI, pos.ion) m / z: 402.0 [M+H] + ;
[0673] 1 H NMR (400MHz, CDCl3) δ7.57 (s, 1H), 7.19 (s, 1H), 4.13 (dd, J = 10.3, 5.7Hz, 1H), 3.89 (d,J=4.8Hz,2H),3.03(s,1H),2.12(dq,J=13.6,6.8Hz,1H),1.00(t,J=6.5Hz,6H).
[0674] Step 4: Synthesis of 5-bromo-7-iodo-2-isopropyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0675] 2-Bromo-4-((1-hydroxy-3-methylbutan-2-yl)oxy)-6-iodopyridin-3-ol (454 mg, 1.13 mmol), triphenylphosphine (590 mg, 2.26 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then diethyl azodicarboxylate (410 mg, 2.37 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2.0 h. The system was concentrated under reduced pressure, and water (30 mL) and ethyl acetate (50 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light pink solid product (402.4 mg, yield 92.79%).
[0676] MS (ESI, pos.ion) m / z: 383.9 [M+H] + ;
[0677] 1 H NMR (400MHz, CDCl3) δ7.20 (s, 1H), 4.44 (dd, J = 11.6, 2.1Hz, 1H), 4.02 (dd, J = 11.6 ,8.0Hz,1H),3.94–3.88(m,1H),2.03–1.89(m,1H),1.05(dd,J=16.2,6.8Hz,6H).
[0678] Step 5: Synthesis of 5-bromo-2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0679] 5-Bromo-7-iodo-2-isopropyl-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (382.4 mg, 1.0 mmol), sodium thiomethoxide (89.0 mg, 1.2 mmol), Pd2dba3 (46.0 mg, 0.05 mmol), XantPhos (58.0 mg, 0.10 mmol) and solvent 1,4-dioxane (30 mL) were added to the reaction flask. After nitrogen ventilation, the mixture was stirred at 100°C and reacted overnight. The mixture was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light yellow oily liquid (126.0 mg, yield 41.59%).
[0680] MS (ESI, pos.ion) m / z: 304.0 [M+H] + ;
[0681] 1 H NMR (400MHz, CDCl3) δ6.67(s,1H),4.40(dd,J=11.5,2.1Hz,1H),4.01(dd,J=11.5,7.9H z,1H),3.94–3.88(m,1H),2.50(s,3H),2.02–1.90(m,1H),1.05(dd,J=17.8,6.8Hz,6H).
[0682] Step 6: Synthesis of N-(3-(2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0683] 5-Bromo-2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (113.0 mg, 0.37 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (160.0 mg, 0.41 mmol), potassium carbonate (100.0 mg, 0.74 mmole) were added to the reaction flask. ol), PdCl2dppf-DCM (45.0 mg, 0.056 mmol), then under nitrogen protection, 1,4-dioxane (12.5 mL) and water (5.0 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C, the reaction was stirred overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light brown solid product (87.8 mg, yield 59.32%).
[0684] MS (ESI, pos.ion) m / z: 399.1 [M+H] + ;
[0685] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.09(s,1H),9.06(s,1H),8.52(s,1H),8.27(d,J=2.8Hz,1H),6.65(s,1H),4.55(d ,J=10.2Hz,1H),4.15–4.02(m,2H),2.64(s,3H),2.07(s,3H),1.96(dq,J=13.6,6.7Hz,1H),1.02(dd,J=14.5,6.8Hz,6H).
[0686] Step 7: Synthesis of N-(3-(2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0687] To the reaction flask were added N-(3-(2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (80.0 mg, 0.20 mmol), cesium carbonate (85.0 mg, 0.26 mmol) and solvent N,N-dimethylformamide (10 mL). Under stirring at room temperature, iodomethane (34.0 mg, 0.24 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h. The system was quenched by adding water (0.5 mL) and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give the product as a light yellow solid (72.8 mg, yield 87.90%).
[0688] MS (ESI, pos.ion) m / z: 413.1 [M+H] + ;
[0689] 1 H NMR (400MHz, DMSO-d6) δ10.16(s,1H),9.08(s,1H),8.61(s,1H),8.26(s,1H),6.66(s,1H),4.54(d,J=10.0Hz,1H),4 .16–4.02(m,2H),3.94(s,3H),2.64(s,3H),2.08(s,3H),1.97(dq,J=13.5,6.9Hz,1H),1.03(dd,J=14.1,6.8Hz,6H).
[0690] Step 8: Synthesis of N-(3-(2-isopropyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0691] N-(3-(2-isopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (65.0 mg, 0.16 mmol), methanol (6.0 mL) and tetrahydrofuran (6.0 mL) were added to the reaction flask, and Oxone (200.0 mg, 0.32 mL) was added under stirring at room temperature. The product was added into a 5-[ ...
[0692] MS (ESI, pos.ion) m / z: 445.2 [M+H] + ;
[0693] 1 H NMR (400MHz, DMSO-d6) δ10.30(s,1H),9.18(s,1H),8.65(s,1H),8.41(s,1H),7.30(s,1H),4.68(dd,J=11.5,1.6Hz,1H),4.26(dd,J=1 1.6,7.5Hz,1H),4.19–4.12(m,1H),3.96(s,3H),3.53(s,3H),2.11(s,3H),1.99(td,J=13.5,6.7Hz,1H),1.05(dd,J=13.2,6.7Hz,6H).
[0694] Example 13 N-(3-(2-cyclopropyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0695] Step 1: Synthesis of 2-((tert-butyldimethylsilyl)oxy)-1-cyclopropylethan-1-ol
[0696] To the reaction flask at 0°C were added 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (1.5 g, 8.61 mmol) and THF (50 mL) in sequence, followed by dropwise addition of cyclopropylmagnesium bromide (17.22 mL, 17.22 mmol, 1 M in THF). After the addition was complete, the mixture was stirred at room temperature for 4 h. Saturated ammonium chloride solution (40 mL) was added to the system to quench the reaction, followed by extraction with ethyl acetate (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 30 / 1) to give the product as a light yellow oily liquid (1.29 g, yield 69.28%).
[0697] 1 H NMR (400MHz, CDCl3) δ3.73(dd,J=10.0,3.4Hz,1H),3.54(dd,J=10.0,7.7Hz,1H),2.97–2.90(m,1H),2.50(s,1H),0.90(s, 9H),0.86–0.76(m,1H),0.57–0.49(m,1H),0.49–0.41(m,1H),0.40–0.34(m,1H),0.23–0.15(m,1H),0.07(d,J=1.9Hz,6H).
[0698] Step 2: Synthesis of 2-bromo-4-(2-((tert-butyldimethylsilyl)oxy)-1-cyclopropylethoxy)-6-iodo-3-(methoxymethoxy)pyridine
[0699] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (2.0 g, 5.56 mmol), 2-((tert-butyldimethylsilyl)oxy)-1-cyclopropylethane-1-ol (1.2 g, 5.56 mmol), triphenylphosphine (2.92 g, 11.12 mmol) and tetrahydrofuran (50 mL) were added to the reaction flask, and then diethyl azodicarboxylate (2.03 g, 11.68 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2 h. The system was concentrated under reduced pressure, and water (60 mL) and ethyl acetate (60 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give the product as a light pink oily liquid (1.62 g, yield 52.22%).
[0700] MS (ESI, pos.ion) m / z: 558.0 [M+H] + ;
[0701] 1 H NMR(400MHz, CDCl3)δ7.30(s,1H),5.18(dd,J=18.0,5.6Hz,2H),3.94–3.87(m,1H),3.87–3.79(m,2H),3.6 4(s,3H),1.12–1.02(m,1H),0.85(s,9H),0.66–0.56(m,2H),0.39–0.32(m,2H),0.04(s,3H),0.00(s,3H).
[0702] Step 3: Synthesis of 2-bromo-4-(1-cyclopropyl-2-hydroxyethoxy)-6-iodopyridin-3-ol
[0703] 2-Bromo-4-(2-((tert-butyldimethylsilyl)oxy)-1-cyclopropylethoxy)-6-iodo-3-(methoxymethoxy)pyridine (1.52 g, 2.72 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then dilute hydrochloric acid (13.60 mL, 54.40 mmol, 4 M) was added. After the addition was complete, the reaction was stirred at room temperature for 2 h. Water (30 mL) and ethyl acetate (60 mL) were added to the system, the liquids were separated, and the aqueous phase was extracted with ethyl acetate (60 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give an off-white solid product (1.02 g, yield 93.66%).
[0704] MS (ESI, pos.ion) m / z: 399.9 [M+H] + ;
[0705] 1 H NMR(400MHz, CDCl3)δ7.90(s,1H),7.24(s,1H),4.00–3.88(m,2H),3.73–3.65(m,1H),3 .31(s,1H),1.17–1.04(m,1H),0.74–0.59(m,2H),0.46–0.38(m,1H),0.33–0.25(m,1H).
[0706] Step 4: Synthesis of 5-bromo-2-cyclopropyl-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0707] 2-Bromo-4-(1-cyclopropyl-2-hydroxyethoxy)-6-iodopyridin-3-ol (1.02 g, 2.55 mmol), triphenylphosphine (1.34 g, 5.1 mmol) and tetrahydrofuran (30 mL) were added to the reaction flask, and then diethyl azodicarboxylate (0.93 g, 5.35 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2.0 h. The system was concentrated under reduced pressure, and water (30 mL) and ethyl acetate (50 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light pink solid product (875.6 mg, yield 89.89%).
[0708] MS (ESI, pos.ion) m / z: 382.0 [M+H] + ;
[0709] 1 H NMR(400MHz, CDCl3)δ7.20(s,1H),4.48(dd,J=11.7,2.3Hz,1H),4.08(dd,J=11.7,7.9Hz,1H), 3.54–3.46(m,1H),1.05–0.94(m,1H),0.79–0.64(m,2H),0.60–0.52(m,1H),0.45–0.37(m,1H).
[0710] Step 5: Synthesis of 5-bromo-2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0711] 5-Bromo-2-cyclopropyl-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (860 mg, 2.25 mmol), sodium thiomethoxide (180.0 mg, 2.48 mmol), Pd2dba3 (100.0 mg, 0.11 mmol), XantPhos (130.0 mg, 0.23 mmol) and 1,4-dioxane (50 mL) were added to the reaction flask. After nitrogen purification, the mixture was stirred at 100°C overnight and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 100 / 1) to give a white solid product (284.0 mg, yield 41.74%).
[0712] MS (ESI, pos.ion) m / z: 302.0 [M+H] + ;
[0713] 1H NMR(400MHz, CDCl3) δ6.67(s,1H),4.45(dd,J=11.6,2.4Hz,1H),4.06(dd,J=11.6,8.0Hz,1H),3.53–3 .46(m,1H),2.50(s,3H),1.05–0.95(m,1H),0.79–0.63(m,2H),0.61–0.52(m,1H),0.45–0.36(m,1H).
[0714] Step 6: Synthesis of N-(3-(2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0715] Add 5-bromo-2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (274.0 mg, 0.91 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (400.0 mg, 1.0 mmol), potassium carbonate (250.0 mg, 1.82 mm Hg) into the reaction flask. ol), PdCl2dppf-DCM (110.0 mg, 0.14 mmol), then under nitrogen protection, 1,4-dioxane (25 mL) and water (10 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred to react overnight, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light brown solid product (293.0 mg, yield 81.51%).
[0716] MS (ESI, pos.ion) m / z: 397.1 [M+H] + ;
[0717] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.09(s,1H),9.06(s,1H),8.52(s,1H),8.27(d,J=2.8Hz,1H),6.67(s,1H),4.54(dd,J=11.5,2.0Hz,1H) ,4.15(dd,J=11.5,7.7Hz,1H),3.70(dd,J=11.8,4.6Hz,1H),2.64(s,3H ),2.07(s,3H),1.12–1.01(m,1H),0.68–0.55(m,2H),0.55–0.44(m,2H).
[0718] Step 7: Synthesis of N-(3-(2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0719] To the reaction flask, N-(3-(2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (283.0 mg, 0.71 mmol), cesium carbonate (300.0 mg, 0.92 mmol) and solvent N,N-dimethylformamide (20 mL) were added dropwise. Under stirring at room temperature, iodomethane (190.0 mg, 1.37 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h. Water (1.0 mL) was added to the system to quench the reaction. The system was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 20 / 1) to give the product as a light yellow solid (237.0 mg, yield 80.88%).
[0720] MS (ESI, pos.ion) m / z: 411.1 [M+H] + ;
[0721] 1 H NMR (400MHz, DMSO-d6) δ10.16(s,1H),9.07(s,1H),8.61(s,1H),8.25(s,1H),6.67(s,1H),4.52(dd,J=11.5,2.1Hz,1H),4.16(dd,J=11.5, 7.5Hz,1H),3.94(s,3H),3.70(dd,J=11.6,4.5Hz,1H),2.63(s,3H),2.08(s,3H),1.13–1.00(m,1H),0.68–0.57(m,2H),0.56–0.42(m,2H).
[0722] Step 8: Synthesis of N-(3-(2-cyclopropyl-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0723] N-(3-(2-cyclopropyl-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (202.0 mg, 0.49 mmol), methanol (16 mL) and tetrahydrofuran (16 mL) were added to the reaction flask. Oxone (600.0 mg, 0.98 mmole) was added under stirring at room temperature. The product was added into a 5-[0-[l-ol]-piperidin-1-yl]-propenesulfonyl]-1-ol) water (16 mL) solution, and the reaction was continued with stirring at room temperature for 2.0 h. A saturated aqueous sodium bicarbonate solution was added to adjust the pH to 7-8. Water (10 mL) was added, and the layers were separated. The aqueous phase was extracted with dichloromethane (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 50 / 1) to give an off-white solid product (193.0 mg, yield 88.63%).
[0724] MS (ESI, pos.ion) m / z: 443.1 [M+H] + ;
[0725] 1 H NMR(400MHz,DMSO-d6)δ10.30(s,1H),9.18(s,1H),8.65(s,1H),8.42(s,1H),7.29(s,1H),4.72–4.60(m ,1H),4.32(dd,J=11.4,7.3Hz,1H),3.97(s,3H),3.81(t,J=7.3Hz,1H),3.53(s,3H),2.11(s,3H),1.16– 1.02(m,1H),0.70–0.59(m,2H),0.58–0.47(m,2H).
[0726] Example 14 N-(3-(2-(Fluoromethyl)-7-(methylsulfonyl)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0727] Step 1: Synthesis of 2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl acetate
[0728] To the reaction flask at 0°C, 2-bromo-6-iodo-3-(methoxymethoxy)pyridin-4-ol (12.0 g, 33.34 mmol), triethylamine (6.75 g, 66.68 mmol) and dichloromethane (250 mL) were added sequentially, and acetyl chloride (4.01 g, 50.01 mmol) was added dropwise with stirring. After the addition was complete, the mixture was moved to room temperature and stirred for 1 h. Water (200 mL) was added to the system for washing, and the liquids were separated. The aqueous phase was extracted with dichloromethane (200 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 10 / 1) to give a light yellow solid product (10.36 g, yield 77.30%).
[0729] MS (ESI, pos.ion) m / z: 401.9 [M+H] + ;
[0730] 1 H NMR (400MHz, CDCl3) δ7.50(s,1H),5.14(s,2H),3.60(s,3H),2.34(s,3H).
[0731] Step 2: Synthesis of 2-bromo-3-hydroxy-6-iodopyridin-4-yl acetate
[0732] 2-Bromo-6-iodo-3-(methoxymethoxy)pyridin-4-yl acetate (10.36 g, 25.77 mmol) and tetrahydrofuran (200 mL) were added to the reaction flask, and aqueous hydrochloric acid solution (128.85 mL, 515.4 mmol, 4 M) was added. After the addition was complete, the reaction was stirred at room temperature for 3 h. Ethyl acetate (100 mL) and water (100 mL) were added, and the layers were separated. The aqueous phase was extracted with ethyl acetate (200 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 1 / 1) to give a light yellow solid product (8.51 g, yield 92.25%).
[0733] MS (ESI, pos.ion) m / z: 357.9 [M+H] + ;
[0734] 1 H NMR (400MHz, DMSO-d6) δ7.31(s,1H),2.32(s,3H).
[0735] Step 3: Synthesis of 2-bromo-6-iodo-3-(oxiran-2-ylmethoxy)pyridin-4-yl acetate
[0736] 2-Bromo-3-hydroxy-6-iodopyridin-4-yl acetate (4.77 g, 13.33 mmol), glycidol (1.54 g, 20.0 mmol), triphenylphosphine (5.24 g, 20.0 mmol) and tetrahydrofuran (50 mL) were added to the reaction flask, and then diethyl azodicarboxylate (3.71 g, 21.33 mmol) was added dropwise. After the addition was complete, the reaction was stirred at room temperature for 2 h. The system was concentrated under reduced pressure, and water (50 mL) and ethyl acetate (50 mL) were added. The layers were separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give the product as a light yellow oily liquid (4.44 g, yield 80.48%).
[0737] MS (ESI, pos.ion) m / z: 413.9 [M+H] + ;
[0738] 1 H NMR(400MHz, CDCl3) δ7.29(s,1H),4.37(dd,J=11.4,2.4Hz,1H),3.96(dd,J=11.4,5.9Hz,1H) ,3.30(td,J=6.4,2.5Hz,1H),2.90(t,J=4.4Hz,1H),2.70(dd,J=4.7,2.6Hz,1H),2.36(s,3H).
[0739] Step 4: Synthesis of (5-bromo-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-2-yl)methanol
[0740] 2-Bromo-6-iodo-3-(oxiran-2-ylmethoxy)pyridin-4-yl acetate (6.24 g, 15.07 mmol) and tetrahydrofuran (200 mL) were added to the reaction flask, and an aqueous sodium hydroxide solution (37.67 mL, 37.67 mmol, 1.0 M) was slowly added. After the addition was complete, the reaction was stirred at room temperature for 4 h. Ethyl acetate (100 mL) and water (100 mL) were added, and the layers were separated. The aqueous phase was extracted with ethyl acetate (100 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 4 / 1) to give a white solid product (5.13 g, yield 91.50%).
[0741] MS (ESI, pos.ion) m / z: 372.1 [M+H] + ;
[0742] 1H NMR(400MHz, CDCl3)δ7.20(s,1H),4.42(dd,J=11.6,1.9Hz,1H),4.35–4.28(m,1H),4.20(dd ,J=7.0,4.9Hz,1H),4.00(d,J=10.3Hz,1H),3.90(d,J=12.3Hz,1H),2.14(d,J=13.2Hz,1H).
[0743] Step 5: Synthesis of (5-bromo-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-2-yl)methanol
[0744] To the reaction flask were added (5-bromo-7-iodo-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-2-yl)methanol (2.50 g, 6.72 mmol), sodium thiomethoxide (590.0 mg, 8.06 mmol), Pd2dba3 (310.0 mg, 0.34 mmol), XantPhos (390.0 mg, 0.67 mmol) and solvent 1,4-dioxane (60 mL). After nitrogen ventilation, the mixture was stirred at 100°C for overnight and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 5 / 1) to give a light yellow solid product (7 mg, yield 36.67%).
[0745] MS (ESI, pos.ion) m / z: 292.0 [M+H] + ;
[0746] 1 H NMR(400MHz,DMSO-d6)δ6.87(s,1H),5.16(t,J=5.6Hz,1H),4.45(dd,J=11.5,1.7Hz,1H ),4.28(d,J=5.1Hz,1H),4.16(dd,J=11.5,7.5Hz,1H),3.72–3.60(m,2H),2.44(s,3H).
[0747] Step 6: Synthesis of 5-bromo-2-(fluoromethyl)-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine
[0748] To the reaction flask at 0°C, (5-bromo-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-2-yl)methanol (200.0 mg, 0.68 mmol) and dichloromethane (20 mL) were added sequentially. A solution of DAST (0.37 g, 2.04 mmol) in dichloromethane (1 mL) was added dropwise with stirring. After the addition was complete, the mixture was stirred at room temperature for 3 h. The system was concentrated under reduced pressure, and the resulting residue was separated and purified by column chromatography (petroleum ether / ethyl acetate (v / v) = 20 / 1) to give a light yellow solid product (82.0 mg, yield 40.72%).
[0749] MS (ESI, pos.ion) m / z: 294.1 [M+H] + ;
[0750] 1 H NMR (400MHz, CDCl3) δ6.68(s,1H),4.76(d,J=4.6Hz,1H),4.64(d,J=4.3Hz,1H),4.53– 4.45(m,1H),4.42(dd,J=11.2,1.5Hz,1H),4.21(dd,J=11.8,7.5Hz,1H),2.51(s,3H).
[0751] Step 7: Synthesis of N-(3-(2-(fluoromethyl)-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0752] 5-Bromo-2-(fluoromethyl)-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridine (75.0 mg, 0.25 mmol), 5-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester (110.0 mg, 0.28 mmol), potassium carbonate (69.0 mg, 0.50 mmol), PdCl2dppf-DCM (31.0 mg, 0.037 mmol), then under nitrogen protection, 1,4-dioxane (10 mL) and water (4 mL) were added, nitrogen was bubbled for 6 minutes, a condenser was connected, nitrogen was ventilated three times, the temperature was raised to 100°C and stirred for 5 hours, and the product was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 25 / 1) to give a light brown solid product (77.0 mg, yield 77.75%).
[0753] MS (ESI, pos.ion) m / z: 389.1 [M+H]+ ;
[0754] 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),10.10(s,1H),9.07(s,1H),8.53(s,1H),8.30(d,J=2.6Hz,1H),6.69(s,1H),4.84(dd,J=11. 4,3.5Hz,1H),4.76–4.66(m,1H),4.63(t,J=5.9Hz,1H),4.59–4.52(m,1H),4.20(dd,J=11.4,7.7Hz,1H),2.65(s,3H),2.08(s,3H).
[0755] Step 8: Synthesis of N-(3-(2-(fluoromethyl)-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide
[0756] To the reaction flask were added N-(3-(2-(fluoromethyl)-7-(methylthio)-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-5-yl)-1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide (117.0 mg, 0.30 mmol), cesium carbonate (130.0 mg, 0.39 mmol) and solvent N,N-dimethylformamide (10 mL). Under stirring at room temperature, iodomethane (51.0 mg, 0.36 mmol) was added dropwise. The reaction was stirred at room temperature for 2.0 h. Water (1.0 mL) was added to the system to quench the reaction. The system was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (dichloromethane / methanol (v / v) = 40 / 1) to give the product as a light yellow solid (65.0 mg, yield 53.62%).
[0757] MS (ESI, pos.ion) m / z: 403.3 [M+H] + ;
[0758] 1 H NMR (400MHz, DMSO-d6) δ10.16(s,1H),9.07(s,1H),8.62(s,1H),8.24(s,1H),6.68(s,1H),5.04–4.86(m,1H),4.86–4.71(m ,1H),4.70–4.59(m,1H),4.56(dd,...
Claims
1. A compound, which is a compound represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof of the compound represented by formula (I), in: X is N or CR x ; Y is N or CR y ; Each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Alkylamino; Ring A is C 3-8 A carbocyclic group or an unsaturated heterocyclic group consisting of 3 to 8 atoms, wherein the C 3-8 The carbocyclic group and the unsaturated heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4, 5 or 6 R 3 Substituted by a substituent; R 1 NH2, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 Substituted by a haloalkyl substituent; R 2 H, D, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 substituted by an alkoxy substituent; Each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group consisting of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl consisting of 5 to 12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group consisting of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5 to 12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 substituted by a hydroxyalkyl substituent; Or, any two adjacent R 3 Together with the atoms to which they are attached, they form C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 substituted by a haloalkoxy substituent; R 4 -S(O)R 5 、-S(O)2R 5 、-S(O)2NR 6 R 7 or -NR 6 S(O)2R 7 ; Each R 5 Independently H, D, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 substituted by an alkoxy substituent; R 6 and R 7 Each independently is H, D, C 1-6 Alkyl, C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 1-6 Alkyl, C 3-8 The cycloalkyl group and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 The alkoxy group is substituted with an alkoxy substituent.
2. The compound according to claim 1, wherein The substructure is as follows: in, Rings A1, A2, A3 and A4 are each independently optionally substituted with 1, 2, 3, 4, 5 or 6 R 3 Substituted by a substituent; Each of V1, V2, V3, V4, V5, V6, V7 and V8 is independently -(CH2)-, -O-, -NH-, -(CH2)-O-, -(CH2)-NH-, -C(=O)-, -NH-C(=O)-, -C(=O)-NH-, -OC(=O)-, -C(=O)-O-, -S-, -S(=O)- or -S(=O)2-.
3. The compound according to claim 1 or 2, wherein The substructure is as follows: Each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , R 3l , R 3m , R 3n , R 3o , R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group consisting of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 Aryl or heteroaryl consisting of 5 to 12 atoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 3-8 Cycloalkyl, heterocyclic group consisting of 3-8 atoms, -C 1-6 Alkylene (C 3-8 Cycloalkyl), -C 1-6 Alkylene (heterocyclic group consisting of 3-8 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5 to 12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 substituted by a hydroxyalkyl substituent; Or, R 3a , R 3b Together with the carbon atoms to which they are attached, R 3c , R 3d Together with the carbon atoms to which they are attached, R 3e , R 3f Together with the carbon atoms to which they are attached, R 3h , R 3i Together with the carbon atoms to which they are attached, R 3j , R 3k Together with the carbon atoms to which they are attached, R 3b , R 3c Together with the carbon atoms to which they are attached, R 3i , R 3j Together with the carbon atoms to which they are attached, R 3l , R 3m Together with the carbon atoms to which they are attached, R 3n , R 3o Together with the carbon atoms to which they are attached, R 3p , R 3q Together with the carbon atoms to which they are attached, R 3m , R 3n Together with the carbon atoms to which they are attached, and, R 3o , R 3p Together with the carbon atoms to which they are attached, they independently form C 3-8 Cycloalkyl or a heterocyclic group consisting of 3-8 atoms, wherein the C 3-8 The cycloalkyl and the heterocyclic group consisting of 3-8 atoms are each independently optionally substituted by 1, 2 or 3 atoms selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 The alkylene group is substituted with a haloalkoxy substituent.
4. The compound according to any one of claims 1 to 3, wherein each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy or C 1-4 Alkylamino; R 1 NH2, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkylamino, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl and C 1-3 Substituted by a haloalkyl substituent; R 2 H, D, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-3 Alkyl, C 1-3 Haloalkyl and C 1-3 The alkoxy group is substituted with an alkoxy substituent.
5. The compound according to any one of claims 1 to 4, wherein each R x and R y are independently H, D, F, Cl, Br, I, -OH, -NH2, -NO2, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, N-methylamino, N-ethylamino or N,N-dimethylamino; R 1 is NH2, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl, N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxymethyl, hydroxyethyl , N-methylamino, N-ethylamino, N,N-dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3 and -CH2CF3; R 2 is H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl. Methyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy.
6. A compound according to any one of claims 1-2 or 4-5, wherein each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5 to 10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 substituted by a hydroxyalkyl substituent; Or, any two adjacent R 3 Together with the atoms to which they are attached, they form C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 3-6 The cycloalkyl and 3-6 atoms of the heterocyclic group are independently optionally substituted by 1, 2 or 3 selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 The alkylene group is substituted with a haloalkoxy substituent.
7. A compound according to any one of claims 1 to 2 or 4 to 6, wherein each R 3 are independently D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, -CHF2CH3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuranyl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuranyl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl; Or, any two adjacent R 3 Together with the atoms to which they are attached, they form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2 or 3 substituents selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
8. A compound according to any one of claims 1 to 7, wherein each R 5 Independently H, D, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C 1-4 substituted by an alkoxy substituent; R 6 and R 7 Each independently is H, D, C 1-4 Alkyl, C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 1-4 Alkyl, C 3-6 The cycloalkyl and the heterocyclic group consisting of 3-6 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl and C 1-4 The alkoxy group is substituted with an alkoxy substituent.
9. The compound according to any one of claims 1 to 8, wherein each R 5 are independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH2F, -CHF2, -CF3, -CH2CF3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy; R 6 and R 7 Each is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl. The pentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl and morpholinyl groups are each independently optionally substituted by 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy and isopropoxy. replace.
10. A compound according to any one of claims 3-5 and 8-9, wherein each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , R 3l , R 3m , R 3n , R 3o , R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 Aryl or heteroaryl composed of 5-10 atoms, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Hydroxyalkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 atoms, -C 1-4 Alkylene (C 3-6 Cycloalkyl), -C 1-4 Alkylene (heterocyclic group consisting of 3-6 atoms), C 6-10 The aryl group and the heteroaryl group consisting of 5 to 10 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 atoms selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 substituted by a hydroxyalkyl substituent; Or, R 3a , R 3b Together with the carbon atoms to which they are attached, R 3c , R 3d Together with the carbon atoms to which they are attached, R 3e , R 3f Together with the carbon atoms to which they are attached, R 3h , R 3i Together with the carbon atoms to which they are attached, R 3j , R 3k Together with the carbon atoms to which they are attached, R 3b , R 3c Together with the carbon atoms to which they are attached, R 3i , R 3j Together with the carbon atoms to which they are attached, R 3l , R 3m Together with the carbon atoms to which they are attached, R 3n , R 3o Together with the carbon atoms to which they are attached, R 3p , R 3q Together with the carbon atoms to which they are attached, R 3m , R 3n Together with the carbon atoms to which they are attached, and, R 3o , R 3p Together with the carbon atoms to which they are attached, they independently form C 3-6 Cycloalkyl or a heterocyclic group consisting of 3 to 6 atoms, wherein the C 3-6 The cycloalkyl and 3-6 atoms of the heterocyclic group are independently optionally substituted by 1, 2 or 3 selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 The alkylene group is substituted with a haloalkoxy substituent.
11. A compound according to any one of claims 3-5 and 8-10, wherein each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , R 3l , R 3m , R 3n , R 3o , R 3p and R 3q are independently H, D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, deuterated methyl, -CH2F, -CHF2, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuranyl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, isopropoxy, hydroxymethyl, hydroxyethyl, methoxymethylene, ethoxymethylene, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, -C 1-2 Alkylene (cyclopropyl), -C 1-2 Alkylene (cyclobutyl), -C 1-2 Alkylene (cyclopentyl), -C 1-2 Alkylene (cyclohexyl), -C 1-2 Alkylene (oxetane), -C 1-2 Alkylene (azetidinyl), -C 1-2 Alkylene (pyrrolidinyl), -C 1-2 Alkylene (tetrahydrofuranyl), -C 1-2 Alkylene (tetrahydropyranyl), -C 1-2 Alkylene (tetrahydrothiopyranyl), -C 1-2 Alkylene (piperidinyl), -C 1-2 Alkylene (piperazinyl), -C 1-2 Alkylene (morpholinyl), phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl are each independently optionally substituted with 1, 2, 3, 4 or 5 substituents selected from D, F, Cl, Br, I, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy, hydroxymethyl and hydroxyethyl; Or, R 3a , R 3b Together with the carbon atoms to which they are attached, R 3c , R 3d Together with the carbon atoms to which they are attached, R 3e , R 3f Together with the carbon atoms to which they are attached, R 3h , R 3i Together with the carbon atoms to which they are attached, R 3j , R 3k Together with the carbon atoms to which they are attached, R 3b , R 3c Together with the carbon atoms to which they are attached, R 3i , R 3j Together with the carbon atoms to which they are attached, R 3l , R 3m and the carbon atoms to which they are attached Together, R. 3n , R 3o Together with the carbon atoms to which they are attached, R 3p , R 3q Together with the carbon atoms to which they are attached, R 3m , R 3n Together with the carbon atoms to which they are attached, and, R 3o , R 3p Together with the carbon atoms to which they are attached, they each independently form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl or morpholinyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl are independently and optionally substituted with 1, 2 or 3 substituents selected from D, F, Cl, Br, I, oxo, -NO2, -CN, -OH, -NH2, methyl, ethyl, n-propyl, isopropyl, -CF3, -CH2CF3, methoxy, ethoxy, isopropoxy and trifluoromethoxy.
12. A compound having one of the following structures, or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof:
13. A pharmaceutical composition comprising the compound according to any one of claims 1 to 12, further comprising at least one of a pharmaceutically acceptable adjuvant, excipient, carrier, and solvent.
14. Use of the compound according to any one of claims 1 to 12 or the pharmaceutical composition according to claim 13 in the preparation of a medicament for preventing, treating, curing or alleviating a disease mediated by TYK2; wherein the disease mediated by TYK2 is multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, atopic dermatitis, vitiligo, lupus nephritis, Crohn's disease, ulcerative colitis, Sjögren's syndrome or scleroderma.
Citation Information
Patent Citations
Substituted heteroaryl compound and composition and application thereof
CN114075220A
Substituted heteroaryl compound and composition and application thereof
CN114075221A
Inhibitors of tyrosine kinase 2 mediated signaling
WO2019178079A1
TYK2 selective inhibitor and use thereof
WO2022242697A1
